QCMD
Quality Control for Molecular Diagnostics

# EQA FOR MOLECULAR INFECTIOUS DISEASE TESTING

# EQA FOR MOLECULAR INFECTIOUS DISEASE TESTING

**QCMD (Quality Control for Molecular Diagnostics) is an independent External Quality Assessment (EQA) / Proficiency Testing (PT) scheme specialising in molecular testing of a wide range of infectious diseases.**

# IMPORTANCE OF EXTERNAL QUALITY ASSESSMENT

**External Quality Assessment (EQA) or Proficiency Testing (PT) provides a means of periodically assessing a laboratory's performance in comparison with other laboratories using the same method and instrument.**

**Unlike Internal Quality Control (IQC), EQA provides an effective method of monitoring a laboratory's bias or accuracy through the analysis of 'blind samples'. Participation in an EQA scheme like QCMD will also support regulatory requirements and will assist in quality improvements.**

EQA plays an essential role in assuring laboratory quality by supporting daily IQC. It facilitates interlaboratory performance comparison and encourages greater standardisation in testing. EQA has a number of functions:

- **Helps maintain and improve the analytical quality of laboratory tests**
- **Provides an objective view of test system performance that IQC alone cannot provide**
- **Helps improve interlaboratory agreement**
- **Initiates corrective and preventative actions to resolve problems**

Furthermore, participating in an EQA scheme is often a prerequisite to gaining accreditation, ISO 15189 states, "the laboratory shall participate in interlaboratory comparisons such as those organised by external quality assessment schemes".

In short, participation in an EQA scheme will give labs greater confidence and will provide evidence that the patient results they are reporting are reliable and accurate.

# BENEFITS


### EXTENSIVE PROGRAMME OFFERING

Boasting the largest selection of molecular EQA programmes for infectious disease testing, you are sure to find what you're looking for.

### FREQUENCY

Choose between one, two and four challenges* per year to suit your laboratory requirements. Reports are available within 2 weeks of the submission deadline (up to 4 weeks for the drug resistance / sequence based schemes), ensuring any corrective actions can be taken quickly.

### HIGH QUALITY MATERIAL

The availability of whole pathogen samples in clinically relevant matrices mimics the performance of patient samples and ensures samples can be used to effectively monitor the performance of the entire testing process.

### INTERNATIONAL ACCREDITATION

Where appropriate the EQA schemes are accredited to ISO 17043:2010 highlighting the superior quality and organisation of the QCMD scheme.

### ONLINE EQA MANAGEMENT SYSTEM

IT EQA Management System (ITEMS) provides an online tool to easily manage all EQA activities from programme registration to submission of results and provision of EQA reports.

### HIGH LEVEL OF PARTICIPATION

With over 10,000 participant registrations in more than 100 countries, peer groups are maximised, increasing statistical validity.

### COMPREHENSIVE REPORTS

Individual reports are provided with each EQA challenge. In line with the requirements of ISO17043, they provide the laboratories with their results and performance assessment in relation to their EQA assessment group (peer review group).

Supplementary reports which include scientific expert commentary may be provided at the end of the EQA cycle if appropriate.



*programme dependent

# HOW IT WORKS

**The QCMD portfolio is extensive covering over 300 target organisms across more than 90 EQA programmes and pilot studies.**

The following diagram provides an overview of the schemes operation.

**EQA REGISTRATION**
Participants may register for EQA programmes online via the participant profile area.

**MANAGEMENT**
All aspects of the scheme can be easily managed using QCMD's unique IT EQA Management System (ITEMS).

**DISTRIBUTION**
Laboratories have a choice of one, two or four distributions per year.

**EQA TESTING**
Laboratory analyses each sample. The number of samples is programme dependent.

**DATA COLLECTION**
Results are returned to QCMD for analysis. Due to our high level of participation a wide variety of workflows are covered.

**EQA REPORTS**
Participant receives a report within 2 weeks (up to 4 weeks for the drug resistance / sequence based schemes) summarising their performance in comparison to their peer group.



# BACTERIAL EQA PROGRAMMES

## BACTERIAL 16S RIBOSOMAL RNA

B16SrRNA20

Designed to evaluate the ability to detect, identify and interpret which bacterial species are provided within each panel member using routine 16S rRNA molecular diagnostic procedures.

| | Available Format(s) |
|---|---|
| **Catalogue Number** | QAB164183_1 |
| **Total Number of Challenges** | 1 |
| **Number of Samples** | 8 to 10 |
| **Distribution / Testing Period** | Q4 |

### Specifications

**Target Pathogen –** May include clinically relevant species of *Serratia, Escherichia, Staphylococcus, Enterococcus* and *Klebsiella*.
**Matrix –** Physiological Buffer
**Sample Volume –** 0.5 ml
**Analysis Type –** Molecular typing
**Format –** Liquid frozen
**Accreditation –** Pending accreditation

## BORDETELLA PERTUSSIS

BPDNA20

Designed to evaluate the ability to detect *Bordetella pertussis* using molecular methods.

| | Available Format(s) |
|---|---|
| **Catalogue Number** | QAB094132_1 |
| **Total Number of Challenges** | 1 |
| **Number of Samples** | 8 to 12 |
| **Distribution / Testing Period** | Q2 |

### Specifications

**Target Pathogen –** *Bordetella pertussis*
**Matrix –** Physiological Buffer
**Sample Volume –** 1.0 ml
**Analysis Type –** Qualitative
**Format –** Liquid frozen
**Accreditation –** ISO17043

## BORRELIA BURGDORFERI SPP. (LYME DISEASE)

BbDNA20

Designed to assess the qualitative detection of *Borrelia burgdorferi* sensu stricto at different concentrations, and the qualitative detection of *B. burgdorferi* genospecies complex at different concentrations.

| | Available Format(s) |
|---|---|
| **Catalogue Number** | QAB114147_1 |
| **Total Number of Challenges** | 1 |
| **Number of Samples** | 8 to 12 |
| **Distribution / Testing Period** | Q3 |

### Specifications

**Target Pathogen –** *Borrelia burgdorferi* spp.
**Matrix –** Microbiological Medium and/or Transport Medium
**Sample Volume –** 1.0 ml
**Analysis Type –** Qualitative
**Format –** Liquid frozen
**Accreditation –** ISO17043

## CHLAMYDIA PSITTACI

CPS20

Designed to evaluate the ability to detect *Chlamydia psittaci* using molecular methods.

| | Available Format(s) |
|---|---|
| **Catalogue Number** | QAB134165_1 |
| **Total Number of Challenges** | 1 |
| **Number of Samples** | 8 to 10 |
| **Distribution / Testing Period** | Q2 |

### Specifications

**Target Pathogen –** *Chlamydia psittaci*
**Matrix –** Transport Medium
**Sample Volume –** 1.0 ml
**Analysis Type –** Qualitative
**Format –** Liquid frozen
**Accreditation –** Pending accreditation

## CHLAMYDIA TRACHOMATIS

### CTDNA20

Designed to assess the qualitative detection of *Chlamydia trachomatis* at various concentrations, and the ability to correctly identify different *C. trachomatis* strains using molecular methods.

| | Available Format(s) | |
|---|---|---|
| **Catalogue Number** | QAB004101_1 | QAB004101_2 |
| **Total Number of Challenges** | 1 | 2 |
| **Number of Samples** | 8 to 12 | 4 to 6 |
| **Distribution / Testing Period** | Q3 | Q1 and Q3 |

### Specifications

**Target Pathogen –** *Chlamydia trachomatis*
**Matrix –** Urine and/or Physiological Buffer
**Sample Volume –** 4.0 ml
**Analysis Type –** Qualitative
**Format –** Liquid frozen
**Accreditation –** ISO17043

## CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE

### CTNg20

Designed to evaluate the ability to detect *Chlamydia trachomatis* and *Neisseria gonorrhoeae* using molecular methods.

| | Available Format(s) | |
|---|---|---|
| **Catalogue Number** | QAB174191_1 | QAB174191_2 |
| **Total Number of Challenges** | 1 | 2 |
| **Number of Samples** | 8 to 12 | 4 to 6 |
| **Distribution / Testing Period** | Q3 | Q1 and Q3 |

### Specifications

**Target Pathogen –** *Chlamydia trachomatis; Neisseria gonorrhoeae*
**Matrix –** Urine and/or Physiological Buffer
**Sample Volume –** 4.0 ml
**Analysis Type –** Qualitative
**Format –** Liquid frozen
**Accreditation –** ISO17043

## CHLAMYDOPHILA PNEUMONIAE

### CP20

Designed to evaluate the ability to detect *Chlamydophila pneumoniae* using molecular methods.

| | Available Format(s) |
|---|---|
| **Catalogue Number** | QAB084107_1 |
| **Total Number of Challenges** | 1 |
| **Number of Samples** | 5 to 10 |
| **Distribution / Testing Period** | Q2 |

### Specifications

**Target Pathogen –** *Chlamydophila pneumoniae*
**Matrix –** Bronchoalveolar Lavage (BAL) and/or Transport Medium
**Sample Volume –** 0.5 ml
**Analysis Type –** Qualitative
**Format –** Liquid frozen
**Accreditation –** ISO17043

## CLOSTRIDIUM DIFFICILE (CD)

### CDDNA20

Designed to evaluate the ability to detect *Clostridium difficile* using molecular methods.

| | Available Format(s) | |
|---|---|---|
| **Catalogue Number** | QAB084125_1 | QAB084125_2 |
| **Total Number of Challenges** | 1 | 2 |
| **Number of Samples** | 8 to 12 | 4 to 6 |
| **Distribution / Testing Period** | Q4 | Q2 and Q4 |

### Specifications

**Target Pathogen –** *Clostridium difficile* (CD)
**Matrix –** Microbiological Medium and/or Synthetic Faecal Matrix
**Sample Volume –** 1.0 ml
**Analysis Type –** Qualitative
**Format –** Liquid frozen
**Accreditation –** ISO17043

## DIARRHEAGENIC ESCHERICHIA COLI

E.COLI20

Designed to evaluate the ability to detect diarrheagenic *Escherichia coli* strains using routine molecular methods.

| | Available Format(s) |
|---|---|
| **Catalogue Number** | QAB154179_1 |
| **Total Number of Challenges** | 1 |
| **Number of Samples** | 8 to 12 |
| **Distribution / Testing Period** | Q4 |

### Specifications

**Target Pathogen –** Diarrheagenic *Escherichia coli*
**Matrix –** Synthetic Faecal Matrix and/or Physiological Buffer
**Sample Volume –** 1.0 ml
**Analysis Type –** Qualitative
**Format –** Liquid frozen
**Accreditation –** Pending accreditation

## EXTENDED SPECTRUM ß-LACTAMASE AND CARBAPENEMASE

ESBL20

Designed to evaluate the ability to detect and determine different ESBL and Carbapenemases in a clinical setting.

| | Available Format(s) |
|---|---|
| **Catalogue Number** | QAB134162_1 |
| **Total Number of Challenges** | 1 |
| **Number of Samples** | 8 to 12 |
| **Distribution / Testing Period** | Q3 |

### Specifications

**Target Pathogen –** Various bacteria carrying ESBL and catbapenemase genes
**Matrix –** Physiological Buffer
**Sample Volume –** 0.5 ml
**Analysis Type –** Molecular typing
**Format –** Liquid frozen
**Accreditation –** Pending accreditation

## GROUP B STREPTOCOCCUS

GBS20

Designed to assess in the qualitative detection of Group B *Streptococcus* using routine molecular methods.

| | Available Format(s) |
|---|---|
| **Catalogue Number** | QAB174200_1 |
| **Total Number of Challenges** | 1 |
| **Number of Samples** | 8 to 12 |
| **Distribution / Testing Period** | Q4 |

### Specifications

**Target Pathogen –** *Streptococcus agalactiae*
**Matrix –** Plasma, Synthetic CSF and/or Transport Medium
**Sample Volume –** 1.0 ml
**Analysis Type –** Qualitative
**Format –** Liquid frozen
**Accreditation –** Pending accreditation

## HELICOBACTER PYLORI

H.PYLORI20

Designed to assess the qualitative detection of *H. pylori* and where appropriate, the identification of *H. pylori* antibiotic resistance status using routine molecular methods.

| | Available Format(s) |
|---|---|
| **Catalogue Number** | QAB164190_1 |
| **Total Number of Challenges** | 1 |
| **Number of Samples** | 5 to 10 |
| **Distribution / Testing Period** | Q3 |

### Specifications

**Target Pathogen –** *Helicobacter pylori*
**Matrix –** Synthetic Faecal Matrix and/or Physiological Buffer
**Sample Volume –** 1.0 ml
**Analysis Type –** Qualitative. Quantitative for information purposes only
**Format –** Liquid frozen
**Accreditation –** Pending accreditation

## LEGIONELLA PNEUMOPHILA

LPDNA20

Designed to evaluate the ability to detect *Legionella pneumophila* using molecular methods.

| | Available Format(s) |
|---|---|
| **Catalogue Number** | QAB044122_1 |
| **Total Number of Challenges** | 1 |
| **Number of Samples** | 8 to 12 |
| **Distribution / Testing Period** | Q1 |

### Specifications

**Target Pathogen –** *Legionella pneumophila*
**Matrix –** Bronchoalveolar lavage (BAL) and/or Transport Medium
**Sample Volume –** 0.5 ml
**Analysis Type –** Qualitative
**Format –** Liquid frozen
**Accreditation –** ISO17043

## METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS (MRSA)

MRSADNA20

Designed to evaluate the ability to detect Methicillin Resistant *Staphylococcus aureus* using molecular methods.

| | Available Format(s) |
|---|---|
| **Catalogue Number** | QAB064124_1 |
| **Total Number of Challenges** | 1 |
| **Number of Samples** | 8 to 12 |
| **Distribution / Testing Period** | Q2 |

### Specifications

**Target Pathogen –** Methicillin Resistant *Staphylococcus aureus* (MRSA)
**Matrix –** Microbiological Medium and/or Transport Medium
**Sample Volume –** 1.2 ml
**Analysis Type –** Qualitative
**Format –** Liquid ready-to-use
**Accreditation –** ISO17043

## METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) – TYPING

***(epidemiology and outbreak studies)***

MRSATP20

Designed to evaluate the ability to use molecular typing for outbreak analysis of Methicillin Resistant *Staphylococcus aureus (MRSA)*.

| | Available Format(s) |
|---|---|
| **Catalogue Number** | QAB074128_1 |
| **Total Number of Challenges** | 1 |
| **Number of Samples** | 8 to 12 |
| **Distribution / Testing Period** | Q2 |

### Specifications

**Target Pathogen –** Methicillin Resistant *Staphylococcus aureus* (MRSA)
**Matrix –** Microbiological Medium and/or Transport Medium
**Sample Volume –** 0.2 ml
**Analysis Type –** Molecular typing
**Format –** Liquid ready-to-use
**Accreditation –** ISO17043

## MYCOBACTERIUM TUBERCULOSIS (MTB)

MTBDNA20

Designed to evaluate the ability to detect *Mycobacterium tuberculosis* using molecular methods.

| | Available Format(s) | |
|---|---|---|
| **Catalogue Number** | QAB014129_1 | QAB014129_2 |
| **Total Number of Challenges** | 1 | 2 |
| **Number of Samples** | 8 to 12 | 4 to 6 |
| **Distribution / Testing Period** | Q4 | Q2 and Q4 |

### Specifications

**Target Pathogen –** *Mycobacterium tuberculosis*
**Matrix –** Sputum and/or Synthetic Sputum and/or Synthetic CSF
**Sample Volume –** 1.0 ml
**Analysis Type –** Qualitative
**Format –** Liquid ready-to-use
**Accreditation –** ISO17043

## MYCOPLASMA PNEUMONIAE

MP20

Designed to evaluate the ability to detect *Mycoplasma pneumoniae* using molecular methods.

| | Available Format(s) |
|---|---|
| **Catalogue Number** | QAB174192_1 |
| **Total Number of Challenges** | 1 |
| **Number of Samples** | 5 to 10 |
| **Distribution / Testing Period** | Q2 |

### Specifications

**Target Pathogen –** *Mycoplasma pneumoniae*
**Matrix –** Bronchoalveolar lavage (BAL) and/or Transport Medium
**Sample Volume –** 0.5 ml
**Analysis Type –** Qualitative
**Format –** Liquid frozen
**Accreditation –** ISO17043

## MYCOPLASMA SPP. (CELL CONTAMINATION)

MYCO20

Designed to evaluate the ability to detect and quantitate *Mycoplasma* species using molecular methods.

| | Available Format(s) |
|---|---|
| **Catalogue Number** | QAB144168_1 |
| **Total Number of Challenges** | 1 |
| **Number of Samples** | 8 to 12 |
| **Distribution / Testing Period** | Q4 |

### Specifications

**Target Pathogen –** *Mycoplasma* species
**Matrix –** Physiological Buffer
**Sample Volume –** 1.2 ml
**Analysis Type –** Qualitative & Quantitative
**Format –** Liquid frozen
**Accreditation –** Pending accreditation

## NEISSERIA GONORRHOEAE

### NgDNA20

Designed to evaluate the ability to detect *Neisseria gonorrhoeae* using molecular technologies.

| | Available Format(s) | |
|---|---|---|
| **Catalogue Number** | QAB034126_1 | QAB034126_2 |
| **Total Number of Challenges** | 1 | 2 |
| **Number of Samples** | 8 to 12 | 4 to 6 |
| **Distribution / Testing Period** | Q3 | Q1 and Q3 |

### Specifications

**Target Pathogen –** *Neisseria gonorrhoeae*
**Matrix –** Urine and/or Physiological Buffer
**Sample Volume –** 4.0 ml
**Analysis Type –** Qualitative
**Format –** Liquid frozen
**Accreditation –** ISO17043

## STAPHYLOCOCCUS AUREUS SPA

### SASPA20

Designed to evaluate the ability to use molecular typing as a technique for identifying *Staphylococcus aureus*.

| | Available Format(s) |
|---|---|
| **Catalogue Number** | QAB134164_1 |
| **Total Number of Challenges** | 1 |
| **Number of Samples** | 6 to 12 |
| **Distribution / Testing Period** | Q2 |

### Specifications

**Target Pathogen –** *Staphylococcus aureus*
**Matrix –** Microbiological Medium and/or Transport Medium
**Sample Volume –** 0.2 ml
**Analysis Type –** Molecular typing
**Format –** Liquid ready-to-use
**Accreditation –** ISO17043

## SYPHILIS

SYPH20

Designed to evaluate the ability to detect *Treponema pallidum* using molecular methods.

| | Available Format(s) |
|---|---|
| **Catalogue Number** | QAB154180_1 |
| **Total Number of Challenges** | 1 |
| **Number of Samples** | 5 to 10 |
| **Distribution / Testing Period** | Q4 |

### Specifications

**Target Pathogen –** *Treponema pallidum*
**Matrix –** Urine and/or Physiological Buffer
**Sample Volume –** 1.0 ml
**Analysis Type –** Qualitative
**Format –** Liquid frozen
**Accreditation –** Pending accreditation

## VANCOMYCIN RESISTANT ENTEROCOCCI (VRE)

VRE20

Designed to evaluate the ability to detect and determine different VRE in clinically relevant sample types using molecular methods.

| | Available Format(s) |
|---|---|
| **Catalogue Number** | QAB134163_1 |
| **Total Number of Challenges** | 1 |
| **Number of Samples** | 8 to 12 |
| **Distribution / Testing Period** | Q3 |

### Specifications

**Target Pathogen –** *Vancomycin Resistant Enterococci*
**Matrix –** Microbiological medium and/or transport medium
**Sample Volume –** 0.5 ml
**Analysis Type –** Molecular Typing
**Format –** Liquid frozen
**Accreditation –** Pending accreditation

# FUNGAL EQA PROGRAMMES

## ASPERGILLUS SPP.

ASPDNA20

Designed to evaluate the ability to detect *Aspergillus* species using molecular methods.

| | Available Format(s) |
|---|---|
| **Catalogue Number** | QAF104140_1 |
| **Total Number of Challenges** | 1 |
| **Number of Samples** | 8 to 12 |
| **Distribution / Testing Period** | Q3 |

### Specifications

**Target Pathogen –** *Aspergillus* species
**Matrix –** Plasma and/or Physiological Buffer and/or Synthetic Sputum
**Sample Volume –** 1.0 ml
**Analysis Type –** Qualitative. Quantitative for information purposes only
**Format –** Liquid frozen
**Accreditation –** ISO17043

## CANDIDA SPP.

CANDNA20

Designed to evaluate the ability to detect *Candida* species using molecular methods.

| | Available Format(s) |
|---|---|
| **Catalogue Number** | QAF124151_1 |
| **Total Number of Challenges** | 1 |
| **Number of Samples** | 8 to 12 |
| **Distribution / Testing Period** | Q3 |

### Specifications

**Target Pathogen –** *Candida* species
**Matrix –** Plasma and/or Physiological Buffer
**Sample Volume –** 1.0 ml
**Analysis Type –** Qualitative
**Format –** Liquid frozen
**Accreditation –** ISO17043

## DERMATOPHYTOSIS

DERMA20

Designed to evaluate the ability to detect *dermatophytes* using routine molecular methods.

| | Available Format(s) |
|---|---|
| **Catalogue Number** | QAF164187_1 |
| **Total Number of Challenges** | 1 |
| **Number of Samples** | 8 to 10 |
| **Distribution / Testing Period** | Q3 |

### Specifications

**Target Pathogen –** *Dermatophytes*
**Matrix –** Physiological Buffer
**Sample Volume –** 1.0 ml
**Analysis Type –** Qualitative
**Format –** Liquid frozen
**Accreditation –** Pending accreditation

## PNEUMOCYSTIS JIROVECII PNEUMONIA (PCP)

PCPDNA20

Designed to evaluate the ability to detect *Pneumocystis jirovecii* using molecular methods.

| | Available Format(s) |
|---|---|
| **Catalogue Number** | QAF114144_1 |
| **Total Number of Challenges** | 1 |
| **Number of Samples** | 8 to 12 |
| **Distribution / Testing Period** | Q3 |

### Specifications

**Target Pathogen –** *Pneumocystis jirovecii*
**Matrix –** Physiological Buffer
**Sample Volume –** 1.0 ml
**Analysis Type –** Qualitative and Quantitative
**Format –** Liquid frozen
**Accreditation –** ISO17043

# MULTI-PATHOGEN/SYNDROMIC PROGRAMMES

## BACTERIAL GASTROENTERITIS

### GastroB20

Designed to evaluate the ability to detect a range of bacterial pathogens known to cause gastroenteritis using routine molecular diagnostic platforms and procedures. The panel members will resemble clinical samples and may include current clinically relevant strains of *Salmonella, Shigella, Yersinia, E.coli 0157, C. difficile* or *Campylobacter* species.

| | Available Format(s) | |
|---|---|---|
| **Catalogue Number** | QAB124153_1 | QAB124153_2 |
| **Total Number of Challenges** | 1 | 2 |
| **Number of Samples** | 8 to 12 | 4 to 6 |
| **Distribution / Testing Period** | Q4 | Q2 & Q4 |

### Specifications

**Target Pathogen –** *Salmonella, Shigella, Yersinia, E.coli 0157, C. difficile* or *Campylobacter* species
**Matrix –** Synthetic Faecal Matrix and/or Physiological Buffer
**Sample Volume –** 1.0 ml
**Analysis Type –** Qualitative
**Format –** Liquid frozen
**Accreditation –** Pending accreditation

## MALDI-TOF

### MALDI20

Designed to evaluate the ability to detect and determine different clinically relevant isolates using MALDI-TOF and other similar mass spectrometry based technologies in the routine microbiology laboratory.

| | Available Format(s) |
|---|---|
| **Catalogue Number** | QAB124155_1 |
| **Total Number of Challenges** | 1 |
| **Number of Samples** | 8 to 12 |
| **Distribution / Testing Period** | Q3 |

### Specifications

**Target Pathogen –** Clinically relevant isolates
**Matrix –** Transport Medium
**Sample Volume –** 1.0 ml
**Analysis Type –** Typing
**Format –** Liquid frozen
**Accreditation –** Pending accreditation

## PARASITIC GASTROENTERITIS

### GastroP20

Designed to evaluate the ability to detect a range of parasitic pathogens known to cause gastroenteritis using routine molecular methods. The panel members will resemble clinical samples and may include current clinically relevant strains of *Giardia, Cryptosporidium, Entamoeba, Dientamoeba and Blastocystis.*

| | Available Format(s) | |
|---|---|---|
| **Catalogue Number** | QAP124154_1 | QAP124154_2 |
| **Total Number of Challenges** | 1 | 2 |
| **Number of Samples** | 8 to 12 | 4 to 6 |
| **Distribution / Testing Period** | Q4 | Q2 & Q4 |

### Specifications

**Target Pathogen –** *Giardia, Cryptosporidium, Entamoeba, Dientamoeba and Blastocystis*
**Matrix –** Synthetic Faecal Matrix and/or Physiological Buffer
**Sample Volume –** 1.0 ml
**Analysis Type –** Qualitative
**Format –** Liquid frozen
**Accreditation –** Pending accreditation

## RESPIRATORY I

### RESPI20

Designed to evaluate the ability to detect and deter mine various Influenza A & B and Respiratory syncytial virus strains. The panel is designed to represent various clinical scenarios.

| | Available Format(s) | |
|---|---|---|
| **Catalogue Number** | QAV164188_1 | QAV164188_2 |
| **Total Number of Challenges** | 1 | 2 |
| **Number of Samples** | 8 to 12 | 4 to 6 |
| **Distribution / Testing Period** | Q3 | Q1 & Q3 |

### Specifications

**Target Pathogen –** Influenza A; Influenza B; Respiratory syncytial virus (RSV)
**Matrix –** Transport Medium
**Sample Volume –** 1.0 ml
**Analysis Type –** Qualitative
**Format –** Liquid frozen
**Accreditation –** Pending accreditation

## RESPIRATORY II

RESPII20

Designed to evaluate the ability to detect and determine human metapneumovirus, respiratory adenoviruses, rhinoviruses, coronaviruses, enterovirus and parainfluenza viruses. The panel is designed to represent various clinical scenarios.

| | Available Format(s) | |
|---|---|---|
| **Catalogue Number** | QAV164189_1 | QAV164189_2 |
| **Total Number of Challenges** | 1 | 2 |
| **Number of Samples** | 8 to 12 | 4 to 6 |
| **Distribution / Testing Period** | Q2 | Q1 & Q3 |

### Specifications

**Target Pathogen –** Human metapneumovirus; respiratory adenoviruses; rhinoviruses; coronaviruses; enterovirus; parainfluenza viruses
**Matrix –** Transport Medium
**Sample Volume –** 1.0 ml
**Analysis Type –** Qualitative
**Format –** Liquid frozen
**Accreditation –** Pending accreditation

## RESPIRATORY III

RESPIII20

Designed to evaluate the ability to detect and determine various *Bordetella pertussis, Legionella pneumoniae, Mycoplasma pneumoniae, Streptococcus pneumoniae* or *Haemophilus influenzae* strains using molecular methods. The panel is designed to represent various clinical scenarios.

| | Available Format(s) | |
|---|---|---|
| **Catalogue Number** | QAM174193_1 | QAM174193_2 |
| **Total Number of Challenges** | 1 | 2 |
| **Number of Samples** | 8 to 12 | 4 to 6 |
| **Distribution / Testing Period** | Q3 | Q1 & Q3 |

### Specifications

**Target Pathogen –** *Bordetella pertussis, Legionella pneumoniae, Mycoplasma pneumoniae, Streptococcus pneumoniae* or *Haemophilus influenzae* strains.
**Matrix –** Transport Medium
**Sample Volume –** 1.0 ml
**Analysis Type –** Qualitative
**Format –** Liquid frozen
**Accreditation –** Pending accreditation

## SEXUALLY TRANSMITTED INFECTIONS I

STI_I20

Designed to evaluate the ability to detect a range of sexually transmitted infections known to cause disease using routine molecular methods. The panel members will resemble clinical samples and may include current clinically relevant strains of *Mycoplasma genitalium, Mycoplasma hominis, Trichomonas vaginalis, Ureaplasma urealyticum* and *Gardnerella vaginalis.*

| | Available Format(s) | |
|---|---|---|
| **Catalogue Number** | QAB154177_1 | QAB154177_2 |
| **Total Number of Challenges** | 1 | 2 |
| **Number of Samples** | 8 to 12 | 4 to 6 |
| **Distribution / Testing Period** | Q4 | Q2 & Q3 |

### Specifications

**Target Pathogen –** *Mycoplasma genitalium, Mycoplasma hominis, Trichomonas vaginalis, Ureaplasma urealyticum* and *Gardnerella vaginalis*
**Matrix –** Urine and/or Physiological Buffer
**Sample Volume –** 4.0 ml
**Analysis Type –** Qualitative
**Format –** Liquid frozen
**Accreditation –** Pending accreditation

## SEXUALLY TRANSMITTED INFECTIONS II

STI_II20

Designed to evaluate the ability to detect a range of sexually transmitted infections known to cause disease using routine molecular methods. The panel members will resemble clinical samples and may include current clinically relevant strains of *Chlamydia trachomatis, Niesseria gonorrhoea, Treponema pallidum* and Herpes Simplex Virus (HSV) strains.

| | Available Format(s) | |
|---|---|---|
| **Catalogue Number** | QAM174201_1 | QAM174201_2 |
| **Total Number of Challenges** | 1 | 2 |
| **Number of Samples** | 8 to 12 | 4 to 6 |
| **Distribution / Testing Period** | Q4 | Q2 & Q3 |

### Specifications

**Target Pathogen –** *Chlamydia trachomatis, Niesseria gonorrhoea, Treponema pallidum* and HSV
**Matrix –** Urine and/or Physiological Buffer
**Sample Volume –** 4.0 ml
**Analysis Type –** Qualitative
**Format –** Liquid frozen
**Accreditation –** Pending accreditation

## VIRAL GASTROENTERITIS

### GastroV20

Designed to evaluate the ability to detect a range of viral pat hogens known to cause gastroenteritis using routine molecular methods. The panel members will resemble clinical samples and may include current clinically relevant strains of norovirus, rotavirus, astrovirus, sapovirus and adenovirus.

| | Available Format(s) | |
|---|---|---|
| **Catalogue Number** | QAV124152_1 | QAV124152_2 |
| **Total Number of Challenges** | 1 | 2 |
| **Number of Samples** | 8 to 12 | 4 to 6 |
| **Distribution / Testing Period** | Q4 | Q2 & Q4 |

### Specifications

**Target Pathogen –** norovirus, rotavirus, astrovirus, sapovirus and adenovirus
**Matrix –** Synthetic Faecal Matrix and/or Physiological Buffer
**Sample Volume –** 1.0 ml
**Analysis Type –** Qualitative
**Format –** Liquid frozen
**Accreditation –** Pending accreditation

# PARASITIC EQA PROGRAMMES

### TOXOPLASMA GONDII

TGDNA20

Designed to evaluate the ability to detect *Toxoplasma gondii* using molecular methods.

| | Available Format(s) | |
|---|---|---|
| **Catalogue Number** | QAP044123_1 | QAP044123_2 |
| **Total Number of Challenges** | 1 | 2 |
| **Number of Samples** | 8 to 12 | 4 to 6 |
| **Distribution / Testing Period** | Q4 | Q2 and Q4 |

## Specifications

**Target Pathogen –** *Toxoplasma gondii*
**Matrix –** Amniotic Fluid and/or Plasma
**Sample Volume –** 2.0 ml
**Analysis Type –** Qualitative
**Format –** Lyophilised
**Accreditation –** ISO17043

# VIRAL EQA PROGRAMMES

### ADENOVIRUS (ADV)

ADVDNA20

Designed to evaluate the ability to detect Adenovirus using molecular methods.

| | Available Format(s) | |
|---|---|---|
| **Catalogue Number** | QAV054133_1 | QAV054133_2 |
| **Total Number of Challenges** | 1 | 2 |
| **Number of Samples** | 8 to 12 | 4 to 6 |
| **Distribution / Testing Period** | Q3 | Q2 and Q3 |

## Specifications

**Target Pathogen –** Adenovirus
**Matrix –** Transport Medium and/or Plasma
**Sample Volume –** 1.0 ml
**Analysis Type –** Qualitative & Quantitative
**Format –** Liquid frozen
**Accreditation –** ISO17043

## B19 VIRUS

B19DNA20

Designed to evaluate the ability to detect and quantitatate B19 virus using molecular methods.

| | Available Format(s) | |
|---|---|---|
| **Catalogue Number** | QAV034116_1 | QAV034116_2 |
| **Total Number of Challenges** | 1 | 2 |
| **Number of Samples** | 8 | 4 |
| **Distribution / Testing Period** | Q3 | Q1 and Q3 |

### Specifications

**Target Pathogen –** B19 virus
**Matrix –** Plasma
**Units of Measurement –** The primary unit is IU/ml however other units will be accepted
**Sample Volume –** 1.2 ml
**Analysis Type –** Qualitative & Quantitative
**Format –** Liquid frozen
**Accreditation –** ISO17043

## BK VIRUS (BKV)

BKDNA20

Designed to evaluate the ability to detect and quantitatate various types of BK virus (BKV) and ensure the reliable quantification of BKV viral load using molecular methods.

| | Available Format(s) | |
|---|---|---|
| **Catalogue Number** | QAV144166_1 | QAV144166_2 |
| **Total Number of Challenges** | 1 | 2 |
| **Number of Samples** | 8 to 12 | 4 to 6 |
| **Distribution / Testing Period** | Q3 | Q2 and Q3 |

### Specifications

**Target Pathogen –** BK virus
**Matrix –** Transport Medium and/or Plasma and/or Urine
**Units of Measurement –** The primary unit is IU/ml however other units will be accepted
**Sample Volume –** 1.0 ml
**Analysis Type –** Qualitative & Quantitative
**Format –** Liquid frozen
**Accreditation –** ISO17043

## CHIKUNGUNYA VIRUS (CHIKV)

CHIKV20

Designed to evaluate the ability to detect chikungunya virus using molecular methods.

| | Available Format(s) |
|---|---|
| **Catalogue Number** | QAV154175_1 |
| **Total Number of Challenges** | 1 |
| **Number of Samples** | 8 to 12 |
| **Distribution / Testing Period** | Q2 |

### Specifications

**Target Pathogen –** Chikungunya virus
**Matrix –** Transport Medium
**Sample Volume –** 1.0 ml
**Analysis Type –** Qualitative. Quantitative for information purposes only
**Format –** Lyophilised
**Accreditation –** Pending accreditation

## CORONAVIRUS (CoV)

CVRNA20

Designed to evaluate the ability to detect coronavirus and different coronavirus genotypes using molecular methods.

| | Available Format(s) |
|---|---|
| **Catalogue Number** | QAV064137_1 |
| **Total Number of Challenges** | 1 |
| **Number of Samples** | 8 to 12 |
| **Distribution / Testing Period** | Q2 |

### Specifications

**Target Pathogen –** Coronavirus
**Matrix –** Transport Medium
**Sample Volume –** 1.0 ml
**Analysis Type –** Qualitative
**Format –** Liquid frozen
**Accreditation –** ISO17043

## CYTOMEGALOVIRUS (CMV) DRIED BLOOD SPOTS

CMVDBS20

Designed to evaluate the ability to detect human cytomegalovirus (CMV) from dried blood spots using molecular methods.

| | Available Format(s) |
|---|---|
| **Catalogue Number** | QAV064127_1 |
| **Total Number of Challenges** | 1 |
| **Number of Samples** | 8 to 12 |
| **Distribution / Testing Period** | Q2 |

### Specifications

**Target Pathogen –** Cytomegalovirus (CMV)
**Matrix –** Dried Blood Spots
**Units of Measurement –** The primary unit is IU/ml however other units will be accepted
**Sample Volume –** 2 x 50µl
**Analysis Type –** Qualitative. Quantitative for information purposes only
**Format –** Dried blood spot
**Accreditation –** ISO17043

## CYTOMEGALOVIRUS (CMV) DRUG RESISTANCE

CMVDR20

Designed to evaluate the ability to detect CMV drug resistant mutations in the kinase UL97 and polymerase UL54 genes using molecular sequencing techniques.

| | Available Format(s) |
|---|---|
| **Catalogue Number** | QAV144169_1 |
| **Total Number of Challenges** | 1 |
| **Number of Samples** | 4 to 7 |
| **Distribution / Testing Period** | Q2 |

### Specifications

**Target Pathogen –** Cytomegalovirus (CMV) Drug Resistance
**Matrix –** Plasma and/or Physiological Buffer
**Sample Volume –** 1.0 ml
**Analysis Type –** Sequence analysis
**Format –** Liquid frozen
**Accreditation –** ISO17043

## CYTOMEGALOVIRUS (CMV)

### CMVDNA20

Designed to evaluate the ability to detect and quantitate human cytomegalovirus (CMV) using molecular methods.

| | Available Format(s) | |
|---|---|---|
| **Catalogue Number** | QAV014120_1 | QAV014120_2 |
| **Total Number of Challenges** | 1 | 2 |
| **Number of Samples** | 8 to 12 | 4 to 6 |
| **Distribution / Testing Period** | Q3 | Q2 and Q3 |

### Specifications

**Target Pathogen –** Cytomegalovirus (CMV)
**Matrix –** Plasma
**Units of Measurement –** The primary unit is IU/ml however other units will be accepted
**Sample Volume –** 1.0 ml
**Analysis Type –** Qualitative & Quantitative
**Format –** Liquid frozen
**Accreditation –** ISO17043

## CYTOMEGALOVIRUS (CMV) WHOLE BLOOD

### CMVWB20

Designed to evaluate the ability to detect and quantitatate CMV from whole blood samples using molecular methods.

| | Available Format(s) | |
|---|---|---|
| **Catalogue Number** | QAV124150_1 | QAV124150_2 |
| **Total Number of Challenges** | 1 | 2 |
| **Number of Samples** | 8 to 12 | 4 to 6 |
| **Distribution / Testing Period** | Q3 | Q2 and Q3 |

### Specifications

**Target Pathogen –** Cytomegalovirus (CMV)
**Matrix –** Whole Blood
**Units of Measurement –** The primary unit is IU/ml however other units will be accepted
**Sample Volume –** 1.0 ml
**Analysis Type –** Qualitative & Quantitative
**Format –** Liquid frozen
**Accreditation –** ISO17043

## DENGUE VIRUS (DENV)

DENVRNA20

Designed to evaluate the ability to detect Dengue virus and ability to distinguish dengue virus from other flaviviruses using molecular methods.

| | Available Format(s) |
|---|---|
| **Catalogue Number** | QAV114148_1 |
| **Total Number of Challenges** | 1 |
| **Number of Samples** | 8 to 12 |
| **Distribution / Testing Period** | Q2 |

### Specifications

**Target Pathogen –** Dengue virus (DENV)
**Matrix –** Transport Medium
**Sample Volume –** 1.0 ml
**Analysis Type –** Qualitative. Quantitative for information purposes only
**Format –** Lyophilised
**Accreditation –** ISO17043

## ENTEROVIRUS (EV)

EVRNA20

Designed to evaluate the ability to detect and quantitate different types of enterovirus (EV) using molecular methods.

| | Available Format(s) | |
|---|---|---|
| **Catalogue Number** | QAV984104_1 | QAV984104_2 |
| **Total Number of Challenges** | 1 | 2 |
| **Number of Samples** | 8 to 12 | 4 to 6 |
| **Distribution / Testing Period** | Q3 | Q1 and Q3 |

### Specifications

**Target Pathogen –** Enterovirus (EV)
**Matrix –** Transport Medium
**Sample Volume –** 1.0 ml
**Analysis Type –** Qualitative. Quantitative for information purposes only
**Format –** Liquid frozen
**Accreditation –** ISO17043

## ENTEROVIRUS TYPING (EV)

EVTP20

Designed to evaluate the ability to correctly identify specific enterovirus (EV) types using routine molecular method and procedures.

| | Available Format(s) |
|---|---|
| **Catalogue Number** | QAV164185_1 |
| **Total Number of Challenges** | 1 |
| **Number of Samples** | 5 to 10 |
| **Distribution / Testing Period** | Q1 |

### Specifications

**Target Pathogen –** Enterovirus (EV)
**Matrix –** Transport Medium
**Sample Volume –** 1.0 ml
**Analysis Type –** Molecular typing
**Format –** Liquid frozen
**Accreditation –** Pending accreditation

## EPSTEIN-BARR VIRUS (EBV)

EBVDNA20

Designed to evaluate the ability to detect and quantitatate Epstein-Barr virus (EBV) in plasma samples using molecular methods.

| | Available Format(s) | |
|---|---|---|
| **Catalogue Number** | QAV024121_1 | QAV024121_2 |
| **Total Number of Challenges** | 1 | 2 |
| **Number of Samples** | 8 to 12 | 4 to 6 |
| **Distribution / Testing Period** | Q3 | Q2 and Q3 |

### Specifications

**Target Pathogen –** Epstein-Barr virus (EBV)
**Matrix –** Transport Medium and/or Plasma
**Units of Measurement –** The primary unit is IU/ml however other units will be accepted
**Sample Volume –** 1.0 ml
**Analysis Type –** Qualitative & Quantitative
**Format –** Liquid frozen
**Accreditation –** ISO17043

## EPSTEIN-BARR VIRUS (EBV) WHOLE BLOOD

EBVWB20

Designed to evaluate the ability to detect and quantitatate Epstein-Barr virus (EBV) in whole blood samples using molecular methods.

| | Available Format(s) | |
|---|---|---|
| **Catalogue Number** | QAV134161_1 | QAV134161_2 |
| **Total Number of Challenges** | 1 | 2 |
| **Number of Samples** | 8 to 12 | 4 to 6 |
| **Distribution / Testing Period** | Q3 | Q2 and Q3 |

### Specifications

**Target Pathogen –** Epstein-Barr virus (EBV)
**Matrix –** Whole Blood
**Units of Measurement –** The primary unit is IU/ml however other units will be accepted
**Sample Volume –** 1.0 ml
**Analysis Type –** Qualitative & Quantitative
**Format –** Liquid frozen
**Accreditation –** ISO17043

## HEPATITIS A VIRUS (HAV)

HAVRNA20

Designed to evaluate the ability to detect Hepatitis A virus (HAV) using molecular methods.

| | Available Format(s) | |
|---|---|---|
| **Catalogue Number** | QAV124156_1 | QAV124156_2 |
| **Total Number of Challenges** | 1 | 2 |
| **Number of Samples** | 8 to 10 | 4 |
| **Distribution / Testing Period** | Q3 | Q1 and Q3 |

### Specifications

**Target Pathogen –** Hepatitis A virus (HAV)
**Matrix –** Plasma
**Sample Volume –** 1.2 ml
**Analysis Type –** Qualitative. Quantitative for information purposes only
**Format –** Liquid frozen
**Accreditation –** ISO17043

## HEPATITIS B VIRUS (HBV)

HBVDNA20

Designed to evaluate the ability to detect and quantitate Hepatitis B virus (HBV) and different HBV genotypes using molecular methods.

| | Available Format(s) | | |
|---|---|---|---|
| **Catalogue Number** | QAV994110_1 | QAV994110_2 | QAV994110_4 |
| **Total Number of Challenges** | 1 | 2 | 4 |
| **Number of Samples** | 8 | 4 | 4 |
| **Distribution / Testing Period** | Q3 | Q1 and Q3 | Q1, Q2, Q3 and Q4 |

### Specifications

**Target Pathogen –** Hepatitis B virus (HBV)
**Matrix –** Plasma
**Units of Measurement –** The primary unit is IU/ml however other units will be accepted
**Sample Volume –** 1.2 ml
**Analysis Type –** Qualitative & Quantitative
**Format –** Liquid frozen
**Accreditation –** ISO17043

## HEPATITIS B VIRUS (HBV) DRUG RESISTANCE

HBVDR20

Designed to evaluate the ability to detect drug resistant mutations in the Hepatitis B virus (HBV) DNA polymerase gene using sequencing techniques and/or LiPA technology.

| | Available Format(s) |
|---|---|
| **Catalogue Number** | QAV124160_1 |
| **Total Number of Challenges** | 1 |
| **Number of Samples** | 4 to 7 |
| **Distribution / Testing Period** | Q3 |

### Specifications

**Target Pathogen –** Hepatitis B virus (HBV) Drug Resistance Mutations
**Matrix –** Plasma
**Sample Volume –** 1.0 ml
**Analysis Type –** Sequence Analysis
**Format –** Liquid frozen
**Accreditation –** ISO17043

## HEPATITIS B VIRUS (HBV) GENOTYPING

HBVGT20

Designed to evaluate the ability to correctly identify Hepatitis B virus (HBV) genotypes using molecular methods.

| | Available Format(s) |
|---|---|
| **Catalogue Number** | QAV064118_1 |
| **Total Number of Challenges** | 1 |
| **Number of Samples** | 8 to 12 |
| **Distribution / Testing Period** | Q1 |

### Specifications

**Target Pathogen –** Hepatitis B virus (HBV) Genotyping
**Matrix –** Plasma
**Sample Volume –** 1.2 ml
**Analysis Type –** Molecular typing
**Format –** Liquid frozen
**Accreditation –** ISO17043

## HEPATITIS C VIRUS (HCV)

HCVRNA20

Designed to evaluate the ability to detect and quantitate Hepatitis C virus (HCV) RNA and different HCV genotypes using molecular methods.

| | Available Format(s) | | |
|---|---|---|---|
| **Catalogue Number** | QAV994112_1 | QAV994112_2 | QAV994112_4 |
| **Total Number of Challenges** | 1 | 2 | 4 |
| **Number of Samples** | 8 | 4 | 4 |
| **Distribution / Testing Period** | Q3 | Q1 and Q3 | Q1, Q2, Q3 and Q4 |

### Specifications

**Target Pathogen –** Hepatitis C virus (HCV)
**Matrix –** Plasma
**Units of Measurement –** The primary unit is IU/ml however other units will be accepted
**Sample Volume –** 1.2 ml
**Analysis Type –** Qualitative & Quantitative
**Format –** Liquid frozen
**Accreditation –** ISO17043

## HEPATITIS C VIRUS (HCV) DRUG RESISTANCE

HCVDR20

Designed to evaluate the ability to detect drug resistant mutations in the Hepatitis C virus (HCV) genotypes 1 and 3 (NS3 and NS5a regions) using sequencing techniques.

| | Available Format(s) |
|---|---|
| **Catalogue Number** | QAV134167_1 |
| **Total Number of Challenges** | 1 |
| **Number of Samples** | 4 to 7 |
| **Distribution / Testing Period** | Q3 |

### Specifications

**Target Pathogen –** Hepatitis C virus (HCV) Drug Resistance Mutations
**Matrix –** Plasma
**Sample Volume –** 1.0 ml
**Analysis Type –** Sequence Analysis
**Format –** Liquid frozen
**Accreditation –** ISO17043

## HEPATITIS C VIRUS (HCV) GENOTYPING

HCVGT20

Designed to evaluate the ability to correctly genotype Hepatitis C virus (HCV) RNA using molecular methods.

| | Available Format(s) |
|---|---|
| **Catalogue Number** | QAV034117_1 |
| **Total Number of Challenges** | 1 |
| **Number of Samples** | 8 to 12 |
| **Distribution / Testing Period** | Q1 |

### Specifications

**Target Pathogen –** Hepatitis C virus (HCV) RNA
**Matrix –** Plasma
**Sample Volume –** 1.2 ml
**Analysis Type –** Molecular typing
**Format –** Liquid frozen
**Accreditation –** ISO17043

## HEPATITIS D VIRUS (HDV)

HDV20

Designed to evaluate the ability to detect Hepatitis D virus (HDV) using molecular methods.

| | Available Format(s) |
|---|---|
| **Catalogue Number** | QAV144170_1 |
| **Total Number of Challenges** | 1 |
| **Number of Samples** | 8 to 10 |
| **Distribution / Testing Period** | Q3 |

### Specifications

**Target Pathogen –** Hepatitis D virus (HDV)
**Matrix –** Plasma
**Sample Volume –** 1.0 ml
**Analysis Type –** Qualitative & Quantitative
**Format –** Liquid frozen
**Accreditation –** Pending accreditation

## HEPATITIS E VIRUS (HEV)

HEVRNA20

Designed to evaluate the ability to detect Hepatitis E virus (HEV) using molecular methods.

| | Available Format(s) |
|---|---|
| **Catalogue Number** | QAV124157_1 |
| **Total Number of Challenges** | 1 |
| **Number of Samples** | 8 to 10 |
| **Distribution / Testing Period** | Q3 |

### Specifications

**Target Pathogen –** Hepatitis E virus (HEV)
**Matrix –** Plasma
**Sample Volume –** 0.6 ml
**Analysis Type –** Qualitative. Quantitative for information purposes only
**Format –** Liquid frozen
**Accreditation –** ISO17043

## HERPES SIMPLEX VIRUS 1 & 2 (HSV)

HSVDNA20

Designed to evaluate the ability to detect different types and concentrations of herpes simplex virus (HSV) using molecular methods.

| | Available Format(s) | |
|---|---|---|
| **Catalogue Number** | QAV994105_1 | QAV994105_2 |
| **Total Number of Challenges** | 1 | 2 |
| **Number of Samples** | 8 to 12 | 4 to 6 |
| **Distribution / Testing Period** | Q3 | Q1 and Q3 |

### Specifications

**Target Pathogen –** Herpes simplex virus 1 & 2 (HSV)
**Matrix –** Transport Medium
**Sample Volume –** 1.0 ml
**Analysis Type –** Qualitative. Quantitative for information purposes only
**Format –** Liquid frozen
**Accreditation –** ISO17043

## HERPES SIMPLEX VIRUS DRUG RESISTANCE

HSVDR20

Designed to evaluate the ability to detect HSV drug resistance mutations in the HSV thymidine kinase (UL23) and DNA polymerase (UL30) genes using routine molecular methods.

| | Available Format(s) |
|---|---|
| **Catalogue Number** | QAV164184_1 |
| **Total Number of Challenges** | 1 |
| **Number of Samples** | 4 to 7 |
| **Distribution / Testing Period** | Q1 |

### Specifications

**Target Pathogen –** HSV drug resistance mutations
**Matrix –** Transport Medium
**Sample Volume –** 1.0 ml
**Analysis Type –** Sequence Analysis
**Format –** Liquid frozen
**Accreditation –** Pending accreditation

## HUMAN HERPES VIRUS 6 (HHV6)

HHV6DNA20

Designed to evaluate the ability to detect various types of Human herpes virus 6 (HHV6) and quantitate HHV6 viral load using molecular methods.

| | Available Format(s) | |
|---|---|---|
| **Catalogue Number** | QAV084119_1 | QAV084119_2 |
| **Total Number of Challenges** | 1 | 2 |
| **Number of Samples** | 8 to 12 | 4 to 6 |
| **Distribution / Testing Period** | Q3 | Q2 and Q3 |

### Specifications

**Target Pathogen –** Human herpes virus 6 (HHV6)
**Matrix –** Transport Medium and/or Plasma
**Units of Measurement –** The primary unit is IU/ml however other units will be accepted
**Sample Volume –** 1.0 ml
**Analysis Type –** Qualitative & Quantitative
**Format –** Liquid frozen
**Accreditation –** ISO17043

## HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) – DNA

HIVDNA20

Designed to evaluate the ability to detect Human Immunodeficiency virus type 1 (HIV-1) pro-viral DNA using molecular methods.

| | Available Format(s) | |
|---|---|---|
| **Catalogue Number** | QAV034114_1 | QAV034114_2 |
| **Total Number of Challenges** | 1 | 2 |
| **Number of Samples** | 8 | 4 |
| **Distribution / Testing Period** | Q3 | Q1 and Q3 |

### Specifications

**Target Pathogen –** Human Immunodeficiency virus type 1 (HIV-1) – DNA
**Matrix –** Physiological Buffer
**Sample Volume –** 0.1 ml
**Analysis Type –** Qualitative. Quantitative for information purposes only
**Format –** Liquid frozen
**Accreditation –** ISO17043

## HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) – DRUG RESISTANCE

HIVDR20

Designed to evaluate the ability to detect drug resistant mutations in the HIV-1 protease and reverse transcriptase genes using molecular sequencing techniques.

| | Available Format(s) |
|---|---|
| **Catalogue Number** | QAV024131_1 |
| **Total Number of Challenges** | 1 |
| **Number of Samples** | 4 to 7 |
| **Distribution / Testing Period** | Q3 |

### Specifications

**Target Pathogen –** Human Immunodeficiency virus type 1 (HIV-1) – Drug Resistance Mutations
**Matrix –** Plasma
**Sample Volume –** 1.0 ml
**Analysis Type –** Sequence Analysis
**Format –** Liquid frozen
**Accreditation –** ISO17043

## HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) – DRUG RESISTANCE (INTEGRASE)

HIVDRint20

Designed to evaluate the ability to detect drug resistant mutations in the HIV-1 integrase gene using molecular sequencing techniques.

| | Available Format(s) |
|---|---|
| **Catalogue Number** | QAV114146_1 |
| **Total Number of Challenges** | 1 |
| **Number of Samples** | 4 to 7 |
| **Distribution / Testing Period** | Q3 |

### Specifications

**Target Pathogen –** Human Immunodeficiency virus type 1 (HIV-1) – Drug Resistance (Integrase) Mutations
**Matrix –** Plasma
**Sample Volume –** 1.0 ml
**Analysis Type –** Sequence Analysis
**Format –** Liquid frozen
**Accreditation –** ISO17043

## HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) – RNA

HIVRNA20

Designed to evaluate the ability to detect and quantitate human immunodeficiency virus (HIV) RNA and different HIV genotypes using molecular methods.

| | Available Format(s) | | |
|---|---|---|---|
| **Catalogue Number** | QAV994108_1 | QAV994108_2 | QAV994108_4 |
| **Total Number of Challenges** | 1 | 2 | 4 |
| **Number of Samples** | 8 | 4 | 4 |
| **Distribution / Testing Period** | Q3 | Q1 and Q3 | Q1, Q2, Q3 and Q4 |

### Specifications

**Target Pathogen –** Human Immunodeficiency virus type 1 (HIV-1) – RNA
**Matrix –** Plasma
**Units of Measurement –** The primary unit is IU/ml however other units will be accepted
**Sample Volume –** 1.2 ml
**Analysis Type –** Qualitative & Quantitative
**Format –** Liquid frozen
**Accreditation –** ISO17043

## HUMAN METAPNEUMOVIRUS (MPV)

MPV20

Designed to evaluate the ability to detect human metapneumovirus (MPV) and different human MPV types using molecular methods.

| | Available Format(s) |
|---|---|
| **Catalogue Number** | QAV054135_1 |
| **Total Number of Challenges** | 1 |
| **Number of Samples** | 8 to 12 |
| **Distribution / Testing Period** | Q2 |

### Specifications

**Target Pathogen –** Human metapneumovirus (MPV)
**Matrix –** Transport Medium
**Sample Volume –** 1.0 ml
**Analysis Type –** Qualitative
**Format –** Liquid frozen
**Accreditation –** ISO17043

## HUMAN PAPILLOMAVIRUS (HPV) – PreservCyt

HPVPRES20

Designed to evaluate the ability to detect different high risk Human Papillomavirus (HPV) types within a PreservCyt® matrix using molecular methods.

| | Available Format(s) | |
|---|---|---|
| **Catalogue Number** | QAV094130_1 | QAV094130_2 |
| **Total Number of Challenges** | 1 | 2 |
| **Number of Samples** | 8 to 12 | 4 to 6 |
| **Distribution / Testing Period** | Q4 | Q2 and Q4 |

### Specifications

**Target Pathogen –** Human Papillomavirus (HPV) – PreservCyt®
**Matrix –** Transport Medium (PreservCyt®)
**Sample Volume –** 4.0 ml
**Analysis Type –** Qualitative
**Format –** Liquid ready-to-use
**Accreditation –** ISO17043

## INFLUENZA A & B VIRUS (FLU)

INFRNA20

Designed to evaluate the ability to detect influenza virus RNA and distinguish Influenza virus types A and B using molecular methods.

| | Available Format(s) | |
|---|---|---|
| **Catalogue Number** | QAV054134_1 | QAV054134_2 |
| **Total Number of Challenges** | 1 | 2 |
| **Number of Samples** | 8 to 12 | 4 to 6 |
| **Distribution / Testing Period** | Q4 | Q2 and Q4 |

### Specifications

**Target Pathogen –** Influenza A & B virus
**Matrix –** Transport Medium
**Sample Volume –** 1.0 ml
**Analysis Type –** Qualitative
**Format –** Liquid frozen
**Accreditation –** ISO17043

## INFLUENZA TYPING (HA)

INFTP20

Designed to evaluate the ability to detect different influenza virus subtypes in addition to the typing and subtyping of influenza viruses using molecular methods.

| | Available Format(s) |
|---|---|
| **Catalogue Number** | QAV064138_1 |
| **Total Number of Challenges** | 1 |
| **Number of Samples** | 5 to 10 |
| **Distribution / Testing Period** | Q4 |

### Specifications

**Target Pathogen –** Influenza Typing (HA)
**Matrix –** Transport Medium
**Sample Volume –** 1.0 ml
**Analysis Type –** Molecular typing
**Format –** Liquid frozen
**Accreditation –** ISO17043

## JC VIRUS (JCV)

JCDNA20

Designed to evaluate the ability to detect and quantitate various types of JC virus (JCV) using molecular methods.

| | Available Format(s) | |
|---|---|---|
| **Catalogue Number** | QAV074106_1 | QAV074106_2 |
| **Total Number of Challenges** | 1 | 2 |
| **Number of Samples** | 8 to 12 | 4 to 6 |
| **Distribution / Testing Period** | Q3 | Q2 and Q3 |

### Specifications

**Target Pathogen –** JC virus (JCV)
**Matrix –** Transport Medium and/or Plasma
**Units of Measurement –** The primary unit is IU/ml however other units will be accepted
**Sample Volume –** 1.0 ml
**Analysis Type –** Qualitative & Quantitative
**Format –** Liquid frozen
**Accreditation –** ISO17043

## MEASLES /MUMPS

MM20

Designed to evaluate the ability to detect mumps and/or measles using routine molecular methods.

| | Available Format(s) |
|---|---|
| **Catalogue Number** | QAV144171_1 |
| **Total Number of Challenges** | 1 |
| **Number of Samples** | 8 to 12 |
| **Distribution / Testing Period** | Q3 |

### Specifications

**Target Pathogen –** Mumps and/or Measles
**Matrix –** Transport Medium
**Sample Volume –** 1.0 ml
**Analysis Type –** Qualitative
**Format –** Liquid frozen
**Accreditation –** Pending accreditation

## MERS CORONAVIRUS (MERS-CoV)

MERS20

Designed to evaluate the ability to detect and determine MERS-CoV from other coronaviruses.

| | Available Format(s) |
|---|---|
| **Catalogue Number** | QAV154181_1 |
| **Total Number of Challenges** | 1 |
| **Number of Samples** | 6 to 10 |
| **Distribution / Testing Period** | Q2 |

### Specifications

**Target Pathogen –** MERS coronavirus (MERS-CoV)
**Matrix –** Transport Medium
**Sample Volume –** 1.0 ml
**Analysis Type –** Qualitative
**Format –** Liquid frozen
**Accreditation –** ISO17043

## NOROVIRUS (NV)

NVRNA20

Designed to evaluate the ability to detect norovirus and different norovirus (NV) genogroups using molecular methods.

| | Available Format(s) | |
|---|---|---|
| **Catalogue Number** | QAV084139_1 | QAV084139_2 |
| **Total Number of Challenges** | 1 | 2 |
| **Number of Samples** | 8 to 12 | 4 to 6 |
| **Distribution / Testing Period** | Q4 | Q2 and Q4 |

### Specifications

**Target Pathogen –** Norovirus (NV)
**Matrix –** Transport Medium and/or Physiological Buffer and/or Synthetic Faecal Matrix
**Sample Volume –** 1.0 ml VTM, 0.1ml Buffer
**Analysis Type –** Qualitative
**Format –** Liquid frozen
**Accreditation –** ISO17043

## PARAINFLUENZA VIRUS (PIV)

PINFRNA20

Designed to evaluate the ability to detect Parainfluenza virus and different Parainfluenza virus (PIV) types using molecular methods.

| | Available Format(s) |
|---|---|
| **Catalogue Number** | QAV064136_1 |
| **Total Number of Challenges** | 1 |
| **Number of Samples** | 8 to 12 |
| **Distribution / Testing Period** | Q2 |

### Specifications

**Target Pathogen –** Parainfluenza virus (PIV)
**Matrix –** Transport Medium
**Sample Volume –** 1.0 ml
**Analysis Type –** Qualitative
**Format –** Liquid frozen
**Accreditation –** ISO17043

## PARECHOVIRUS (HPeV)

PeVRNA20

Designed to evaluate the ability to detect Parainfluenza virus and different Parainfluenza virus types using molecular methods.

| | Available Format(s) | |
|---|---|---|
| **Catalogue Number** | QAV114145_1 | QAV114145_2 |
| **Total Number of Challenges** | 1 | 2 |
| **Number of Samples** | 8 to 12 | 4 to 6 |
| **Distribution / Testing Period** | Q3 | Q1 and Q3 |

### Specifications

**Target Pathogen –** Parechovirus (HPeV)
**Matrix –** Transport Medium
**Sample Volume –** 1.0 ml
**Analysis Type –** Qualitative
**Format –** Liquid frozen
**Accreditation –** ISO17043

## RESPIRATORY SYNCYTIAL VIRUS (RSV)

RSV20

Designed to evaluate the ability to detect different types of Respiratory syncytial virus (RSV) using molecular methods.

| | Available Format(s) | |
|---|---|---|
| **Catalogue Number** | QAV054142_1 | QAV054142_2 |
| **Total Number of Challenges** | 1 | 2 |
| **Number of Samples** | 8 to 12 | 4 to 6 |
| **Distribution / Testing Period** | Q4 | Q2 and Q4 |

### Specifications

**Target Pathogen –** Respiratory syncytial virus (RSV)
**Matrix –** Transport Medium
**Sample Volume –** 1.0 ml
**Analysis Type –** Qualitative
**Format –** Liquid frozen
**Accreditation –** ISO17043

## RHINOVIRUS (RV)

RVRNA20

Designed to evaluate the ability to detect rhinovirus and different rhinovirus (RV) genotypes using molecular methods.

| | Available Format(s) |
|---|---|
| **Catalogue Number** | QAV064143_1 |
| **Total Number of Challenges** | 1 |
| **Number of Samples** | 8 to 12 |
| **Distribution / Testing Period** | Q2 |

### Specifications

**Target Pathogen –** Rhinovirus (RV)
**Matrix –** Transport Medium
**Sample Volume –** 1.0 ml
**Analysis Type –** Qualitative
**Format –** Liquid frozen
**Accreditation –** ISO17043

## VARICELLA-ZOSTER VIRUS (VZV)

VZVDNA20

Designed to evaluate the ability to detect different types and concentrations of Varicella-Zoster virus (VZV) using molecular methods.

| | Available Format(s) | |
|---|---|---|
| **Catalogue Number** | QAV034103_1 | QAV034103_2 |
| **Total Number of Challenges** | 1 | 2 |
| **Number of Samples** | 8 to 12 | 4 to 6 |
| **Distribution / Testing Period** | Q3 | Q1 and Q3 |

### Specifications

**Target Pathogen –** Varicella-Zoster virus (VZV)
**Matrix –** Transport Medium
**Sample Volume –** 1.0 ml
**Analysis Type –** Qualitative. Quantitative for information purposes only
**Format –** Liquid frozen
**Accreditation –** ISO17043

## WEST NILE VIRUS (WNV)

WNVRNA20

Designed to evaluate the ability to detect West Nile virus and distinguish West Nile virus from other flaviviruses using molecular methods.

| | Available Format(s) |
|---|---|
| **Catalogue Number** | QAV104141_1 |
| **Total Number of Challenges** | 1 |
| **Number of Samples** | 8 to 12 |
| **Distribution / Testing Period** | Q2 |

### Specifications

**Target Pathogen –** West Nile virus (WNV)
**Matrix –** Transport Medium
**Sample Volume –** 1.0 ml
**Analysis Type –** Qualitative. Quantitative for information purposes only
**Format –** Lyophilised
**Accreditation –** ISO17043

## ZIKA VIRUS

ZIKA20

Designed to evaluate the ability to detect Zika virus and determine the proficiency of laboratories in distinguishing Zika virus from other flaviviruses.

| | Available Format(s) |
|---|---|
| **Catalogue Number** | QAV164186_1 |
| **Total Number of Challenges** | 1 |
| **Number of Samples** | 8 to 12 |
| **Distribution / Testing Period** | Q2 |

### Specifications

**Target Pathogen –** Zika virus
**Matrix –** Transport Medium
**Sample Volume –** 1.0 ml
**Analysis Type –** Qualitative. Quantitative for information purposes only
**Format –** Lyophilised
**Accreditation –** Pending accreditation

# PILOT STUDIES

## ARTHROPOD-BORNE VIRUSES

ARBO20

Designed to evaluate the ability to detect different Arthropod-borne viruses (including viruses from *Flavi-, Toga-, Bunya-*, and/or *Reoviridae* families) using routine molecular methods. The panel is designed to represent various clinical scenarios and may include medically important arboviruses such as Tick-borne encephalitis viruses, sandfly fever viruses, Japanese encephalitis viruses, rift valley fever viruses, Usutu virus, Murray Valley encephalitis virus and St. Louis encephalitis virus.

| | Available Format(s) |
|---|---|
| **Catalogue Number** | QAM194206_1 |
| **Total Number of Challenges** | 1 |
| **Number of Samples** | 8 to 12 |
| **Distribution / Testing Period** | Q2 |

### Specifications

**Target Pathogen –** Tick-borne encephalitis viruses, sandfly fever viruses, Japanese encephalitis viruses, rift valley fever viruses,Usutu virus, Murray Valley encephalitis virus and St. Louis encephalitis virus
**NA Target Source –** Cultured and/or Clinical material
**Matrix –** Transport Medium
**Sample Volume –** 1 ml
**Analysis Type –** Qualitative. Quantitative for information purposes only
**Format –** Lyophilised

## ATYPICAL MYCOBACTERIUM

NTM20

Designed to evaluate the ability to detect and differentiate Atypical mycobacterium or non-tuberculous mycobacterium using routine molecular methods.

| | Available Format(s) |
|---|---|
| **Catalogue Number** | QAB194208_1 |
| **Total Number of Challenges** | 1 |
| **Number of Samples** | 8 to 12 |
| **Distribution / Testing Period** | Q2 |

### Specifications

**Target Pathogen –** Atypical mycobacterium or non-tuberculous mycobacterium (NTM)
**NA Target Source –** Cultured and/or Clinical material
**Matrix –** Transport Medium and/or Physiological Buffer
**Sample Volume –** 1 ml
**Analysis Type –** Qualitative
**Format –** Liquid ready-to-use

## CENTRAL NERVOUS SYSTEM I (VIRAL MENINGITIS AND ENCEPHALITIS)

CNSI20

Designed to evaluate the ability to detect and determine various enterovirus, parechovirus, Herpes simplex virus 1/2, Varicella-Zoster virus and JC virus strains using routine molecular methods. The panel is designed to represent various clinical scenarios.

| | Available Format(s) | |
|---|---|---|
| **Catalogue Number** | QAV174195_1 | QAV174195_2 |
| **Total Number of Challenges** | 1 | 2 |
| **Number of Samples** | 8 to 12 | 4 to 6 |
| **Distribution / Testing Period** | Q4 | Q2 & Q4 |

### Specifications

**Target Pathogen –** Various enterovirus, parechovirus, HSV1, HSV2, VZV and JCV
**NA Target Source –** Cultured and/or Clinical material
**Matrix –** Transport Medium
**Sample Volume –** 1.0 ml
**Analysis Type –** Qualitative. Quantitative for information purposes only
**Format –** Liquid frozen

## CENTRAL NERVOUS SYSTEM II (NON-VIRAL MENINGITIS AND ENCEPHALITIS)

CNSII20

Designed to evaluate the ability to detect and determine various *Listeria* spp., *Neisseria meningitidis, Streptococcus pneumoniae, Streptococcus agalactiae, Escherichia coli* K1, *Aspergillus* spp. and *Haemophilus influenzae* strains using routine molecular methods. The panel is designed to represent various clinical scenarios.

| | Available Format(s) | |
|---|---|---|
| **Catalogue Number** | QAM174196_1 | QAM174196_2 |
| **Total Number of Challenges** | 1 | 2 |
| **Number of Samples** | 8 to 12 | 4 to 6 |
| **Distribution / Testing Period** | Q4 | Q2 & Q4 |

### Specifications

**Target Pathogen –** Various *Listeria* spp., *Neisseria meningitidis*, *Streptococcus pneumoniae*, *Streptococcus agalactiae*, *E coli* K1, *Aspergillus* spp. or *Haemophilus influenzae* strains
**NA Target Source –** Cultured and/or Clinical material
**Matrix –** Transport Medium
**Sample Volume –** 1.0 ml
**Analysis Type –** Qualitative. Quantitative for information purposes only
**Format –** Liquid frozen

## HUMAN IMMUNODEFICIENCY VIRUS TYPE 2 (HIV-2)

HIV2_20

This pilot study assesses the proficiency of laboratories in detection and quantitation of human immunodeficiency virus type 2 (HIV-2).

| | Available Format(s) | |
|---|---|---|
| **Catalogue Number** | QAV204212_1 | QAV204212_2 |
| **Total Number of Challenges** | 1 | 2 |
| **Number of Samples** | 8 | 4 |
| **Distribution / Testing Period** | Q3 | Q1 & Q3 |

### Specifications

**Target Pathogen –** Human Immunodeficiency virus type 2
**NA Target Source –** Cultured and/or Clinical material
**Matrix –** Plasma
**Analysis Type –** Qualitative & Quantitative
**Format –** Liquid frozen

## HUMAN PAPILLOMAVIRUS (SUREPATH)

HPVSURE20

Designed to evaluate the ability to detect different high-risk Human Papillomavirus (HPV) types within a SurePath™ matrix using routine molecular methods.

| | Available Format(s) |
|---|---|
| **Catalogue Number** | QAV184204_1 |
| **Total Number of Challenges** | 1 |
| **Number of Samples** | 8 to 12 |
| **Distribution / Testing Period** | Q4 |

### Specifications

**Target Pathogen –** Human papillomavirus
**NA Target Source –** Clinical material and/or cell lines containing HPV
**Matrix –** Transport Medium (SurePath)
**Sample Volume –** 2.0 ml
**Analysis Type –** Qualitative
**Format –** Lyophilised

## MYCOBACTERIUM TUBERCULOSIS DRUG RESISTANCE

MTBDR20

Designed to evaluate the ability to detect and differentiate *Mycobacterium tuberculosis* drug resistant strains using routine molecular methods.

| | Available Format(s) |
|---|---|
| **Catalogue Number** | QAB194209_1 |
| **Total Number of Challenges** | 1 |
| **Number of Samples** | 6 to 10 |
| **Distribution / Testing Period** | Q4 |

### Specifications

**Target Pathogen –** *Mycobacterium tuberculosis*
**NA Target Source –** Cultured and/or Clinical material
**Matrix –** Sputum and/or Synthetic Sputum and/or Synthetic CSF
**Analysis Type –** Molecular typing
**Format –** Liquid ready-to-use

## MYCOPLASMA GENITALIUM

MG20

Designed to evaluate the ability to detect *Mycoplasma genitalium* using routine molecular methods.

| | Available Format(s) |
|---|---|
| **Catalogue Number** | QAB184205_1 |
| **Total Number of Challenges** | 1 |
| **Number of Samples** | 6 to 10 |
| **Distribution / Testing Period** | Q3 |

### Specifications

**Target Pathogen –** *Mycoplasma genitalium*
**NA Target Source –** Cultured and/or Clinical material
**Matrix –** Urine and/or Saline
**Sample Volume –** 4.0 ml
**Analysis Type –** Qualitative
**Format –** Liquid frozen

## SEPSIS

### SEPSIS20

Designed to evaluate a range of pathogens associated with sepsis such as *Staphylococcus*, *Serratia, Escherichia coli, Enterococcus, Streptococcus, Klebsiella*, coagulase-negative *Staphylococcus*, *Pseudomonas* and *Candida* spp. using molecular methods.

| | Available Format(s) |
|---|---|
| **Catalogue Number** | QAB164178_1 |
| **Total Number of Challenges** | 1 |
| **Number of Samples** | 8 to 12 |
| **Distribution / Testing Period** | Q4 |

### Specifications

**Target Pathogen –** *Staphylococcus*, *Serratia, Escherichia coli, Enterococcus, Streptococcus, Klebsiella*, coagulase-negative *Staphylococcus*, *Pseudomonas* and *Candida* spp.
**Matrix –** Whole Blood and/or Plasma
**Sample Volume –** 1.0 ml
**Analysis Type –** Qualitative
**Format –** Liquid frozen
**Accreditation –** Pending accreditation

## TORQUE TENO VIRUS

### TTV20

Designed to evaluate the ability to detect Torque teno virus (TTV) using routine molecular diagnostic platforms and procedures.

| | Available Format(s) |
|---|---|
| **Catalogue Number** | QAV184203_1 |
| **Total Number of Challenges** | 1 |
| **Number of Samples** | 6 to 10 |
| **Distribution / Testing Period** | Q4 |

### Specifications

**Target Pathogen –** Torque teno virus
**NA Target Source –** Cultured and/or Clinical material
**Matrix –** Transport Medium
**Sample Volume –** 1.0 ml
**Analysis Type –** Qualitative
**Format –** Liquid frozen

## TRANSPLANTATION (VIRAL)

TRANS20

Designed to evaluate the ability to detect and determine various cytomegalovirus, Epstein-Barr virus, Human herpes virus 6, BK virus, B19 virus and adenovirus strains. The panel is designed to represent various clinical scenarios. Participating laboratories will be expected to test each panel using their appropriate molecular methods and to report their individual test results to QCMD.

| | Available Format(s) | |
|---|---|---|
| **Catalogue Number** | QAM174198_1 | QAM174198_2 |
| **Total Number of Challenges** | 1 | 2 |
| **Number of Samples** | 8 to 12 | 4 to 6 |
| **Distribution / Testing Period** | Q3 | Q2 & Q4 |

### Specifications

**Target Pathogen –** Various EBV, HHV6, BKV, B19 and ADV
**NA Target Source –** Cultured and/or Clinical material
**Matrix –** Plasma and/or Transport Medium
**Sample Volume –** 1.0 ml
**Analysis Type –** Qualitative & Quantitative
**Format –** Liquid frozen

## TRICHOMONAS VAGINALIS

TV20

Designed to evaluate the ability to detect *Trichomonas vaginalis* using routine molecular methods.

| | Available Format(s) |
|---|---|
| **Catalogue Number** | QAP184202_1 |
| **Total Number of Challenges** | 1 |
| **Number of Samples** | 6 to 10 |
| **Distribution / Testing Period** | Q3 |

### Specifications

**Target Pathogen –** *Trichomonas vaginalis*
**NA Target Source –** Cultured and/or Clinical material
**Matrix –** Transport Medium
**Sample Volume –** 1.0 ml
**Analysis Type –** Qualitative
**Format –** Liquid frozen

## VIRAL METAGENOMICS NGS

NGSmeta_20

This EQA pilot study aims to assess performance of existing metagenomics protocols as currently implemented by participating laboratories. Samples will be provided which will mimic cerebrospinal fluid samples containing known viral pathogens including enterovirus, herpes simplex virus and influenza virus.

Performance will be assessed based on the qualitative identification of viruses present in the samples, at the family, genus, species and subtype levels.

| | Available Format(s) |
|---|---|
| **Catalogue Number** | QAV204213_1 |
| **Total Number of Challenges** | 1 |
| **Number of Samples** | 4 to 7 |
| **Distribution / Testing Period** | Q4 |

### Specifications

**Target Pathogen –** Enterovirus, herpes simplex virus and influenza virus.
**NA Target Source** – Cultured material
**Matrix –** Synthetic CSF + human cell lines
**Sample Volume –** 1.0ml
**Analysis Type –** Sequence Analysis
**Format –** Liquid frozen

## YELLOW FEVER VIRUS

YFV20

Designed to evaluate the ability to detect Yellow fever virus and to distinguish Yellow fever virus from other flaviviruses using routine molecular methods.

| | Available Format(s) |
|---|---|
| **Catalogue Number** | QAM194207_1 |
| **Total Number of Challenges** | 1 |
| **Number of Samples** | 8 to 12 |
| **Distribution / Testing Period** | Q2 |

### Specifications

**Target Pathogen –** Yellow fever virus
**NA Target Source –** Cultured and/or Clinical material
**Matrix –** Transport Medium
**Sample Volume –** 1.0 ml
**Analysis Type –** Qualitative. Quantitative for information purposes only
**Format –** Lyophilised

# INDEX

# PILOT STUDIES

# APPENDIX

| TARGET PATHOGEN | | | | | | | PAGE NUMBER |
|---|---|---|---|---|---|---|---|
| PROGRAMME CODE | CATALOGUE NUMBER | NO. OF CHALLENGES | PANEL MEMBERS PER CHALLENGE | DISTRIBUTION DATE(S)/ TESTING PERIOD | SHIPPING CONDITIONS | ANALYSIS TYPE | PROGRAMME TYPE |
| **Adenovirus** | | | | | | | **Pg 22** |
| ADVDNA20 | QAV054133_1<br>QAV054133_2 | 1<br>2 | 8 to 12<br>4 to 6 | Q3<br>Q2, Q3 | Dry-ice | Qualitative & Quantitative | Viral EQA |
| **Arthropod-borne viruses** | | | | | | | **Pg 45** |
| ARBO20 | QAM194206_1 | 1 | 8 to 12 | Q2 | Ambient | Qualitative | Pilot Study |
| ***Aspergillus* spp.** | | | | | | | **Pg 15** |
| ASPDNA20 | QAF104140_1 | 1 | 8 to 12 | Q3 | Dry-ice | Qualitative | Fungal EQA |
| **Atypical mycobacterium** | | | | | | | **Pg 45** |
| NTM20 | QAB194208_1 | 1 | 8 to 12 | Q2 | Ambient | Qualitative | Pilot Study |
| **B19 virus** | | | | | | | **Pg 23** |
| B19DNA20 | QAV034116_1<br>QAV034116_2 | 1<br>2 | 8<br>4 | Q3<br>Q1, Q3 | Dry-ice | Qualitative & Quantitative | Viral EQA |
| **Bacterial 16S Ribosomal RNA** | | | | | | | **Pg 4** |
| B16SrRNA20 | QAB164183_1 | 1 | 8 to 10 | Q4 | Dry-ice | Typing | Bacterial EQA |
| **Bacterial Gastroenteritis** | | | | | | | **Pg 17** |
| GastroB20 | QAB124153_1<br>QAB124153_2 | 1<br>2 | 8 to 12<br>4 to 6 | Q4<br>Q2 & Q4 | Dry-ice | Qualitative | Multi-Pathogen / Syndromic EQA |
| **BK virus (BKV)** | | | | | | | **Pg 23** |
| BKDNA20 | QAV144166_1<br>QAV144166_2 | 1<br>2 | 8 to 12<br>4 to 6 | Q3<br>Q2, Q3 | Dry-ice | Qualitative & Quantitative | Viral EQA |
| ***Bordetella pertussis*** | | | | | | | **Pg 4** |
| BPDNA20 | QAB094132_1 | 1 | 8 to 12 | Q2 | Dry-ice | Qualitative | Bacterial EQA |
| ***Borrelia burgdorferi* spp. (Lyme Disease)** | | | | | | | **Pg 5** |
| BbDNA20 | QAB114147_1 | 1 | 8 to 12 | Q3 | Dry-ice | Qualitative | Bacterial EQA |
| ***Candida* spp.** | | | | | | | **Pg 15** |
| CANDNA20 | QAF124151_1 | 1 | 8 to 12 | Q3 | Dry-ice | Qualitative | Fungal EQA |
| **Central Nervous System I (Viral Meningitis and Encephalitis)** | | | | | | | **Pg 46** |
| CNSI20 | QAV174195_1<br>QAV174195_2 | 1<br>2 | 8 to 12<br>4 to 6 | Q4<br>Q2 & Q4 | Dry-ice | Qualitative | Pilot Study |
| **Central Nervous System II (Non-viral Meningitis and Encephalitis)** | | | | | | | **Pg 46** |
| CNSII20 | QAM174196_1<br>QAM174196_2 | 1<br>2 | 8 to 12<br>4 to 6 | Q4<br>Q2 & Q4 | Dry-ice | Qualitative | Pilot Study |
| **Chikungunya virus (CHIKV)** | | | | | | | **Pg 24** |
| CHIKV20 | QAV154175_1 | 1 | 8 to 12 | Q2 | Ambient | Qualitative | Viral EQA |
| ***Chlamydia psittaci*** | | | | | | | **Pg 5** |
| CPS20 | QAB134165_1 | 1 | 8 to 10 | Q2 | Dry-ice | Qualitative | Bacterial EQA |
| ***Chlamydia trachomatis*** | | | | | | | **Pg 6** |
| CTDNA20 | QAB004101_1<br>QAB004101_2 | 1<br>2 | 8 to 12<br>4 to 6 | Q3<br>Q1, Q3 | Dry-ice | Qualitative | Bacterial EQA |

| TARGET PATHOGEN | | | | | | | PAGE NUMBER |
|---|---|---|---|---|---|---|---|
| PROGRAMME CODE | CATALOGUE NUMBER | NO. OF CHALLENGES | PANEL MEMBERS PER CHALLENGE | DISTRIBUTION DATE(S)/ TESTING PERIOD | SHIPPING CONDITIONS | ANALYSIS TYPE | PROGRAMME TYPE |
| ***Chlamydia trachomatis* and *Neisseria gonorrhoeae*** | | | | | | | **Pg 6** |
| CTNg20 | QAB174191_1<br>QAB174191_2 | 1<br>2 | 8 to 12<br>4 to 6 | Q3<br>Q1, Q3 | Dry-ice | Qualitative | Multi-Pathogen / Syndromic EQA |
| ***Chlamydophila pneumoniae*** | | | | | | | **Pg 7** |
| CP20 | QAB084107_1 | 1 | 5 to 10 | Q2 | Dry-ice | Qualitative | Bacterial EQA |
| ***Clostridium difficile* (CD)** | | | | | | | **Pg 7** |
| CDDNA20 | QAB084125_1<br>QAB084125_2 | 1<br>2 | 8 to 12<br>4 to 6 | Q4<br>Q2, Q4 | Dry-ice | Qualitative | Bacterial EQA |
| **Coronavirus (CoV)** | | | | | | | **Pg 24** |
| CVRNA20 | QAV064137_1 | 1 | 8 to 12 | Q2 | Dry-ice | Qualitative | Viral EQA |
| **Cytomegalovirus (CMV) Dried Blood Spots** | | | | | | | **Pg 25** |
| CMVDBS20 | QAV064127_1 | 1 | 8 to 12 | Q2 | Ambient | Qualitative | Viral EQA |
| **Cytomegalovirus (CMV) Drug Resistance** | | | | | | | **Pg 25** |
| CMVDR20 | QAV144169_1 | 1 | 4 to 7 | Q2 | Dry-ice | Drug Resistance / Sequencing | Viral EQA |
| **Cytomegalovirus (CMV)** | | | | | | | **Pg 26** |
| CMVDNA20 | QAV014120_1<br>QAV014120_2 | 1<br>2 | 8 to 12<br>4 to 6 | Q3<br>Q2, Q3 | Dry-ice | Qualitative & Quantitative | Viral EQA |
| **Cytomegalovirus (CMV) Whole Blood** | | | | | | | **Pg 26** |
| CMVWB20 | QAV124150_1<br>QAV124150_2 | 1<br>2 | 8 to 12<br>4 to 6 | Q3<br>Q2, Q3 | Dry-ice | Qualitative & Quantitative | Viral EQA |
| **Dengue virus (DENV)** | | | | | | | **Pg 27** |
| DENVRNA20 | QAV114148_1 | 1 | 8 to 12 | Q2 | Ambient | Qualitative | Viral EQA |
| **Dermatophytosis** | | | | | | | **Pg 16** |
| DERMA20 | QAF164187_1 | 1 | 8 to 10 | Q3 | Dry-ice | Qualitative | Fungal EQA |
| **Diarrheagenic *Escherichia coli*** | | | | | | | **Pg 8** |
| E.COLI20 | QAB154179_1 | 1 | 8 to 12 | Q4 | Dry-ice | Qualitative | Bacterial EQA |
| **Enterovirus (EV)** | | | | | | | **Pg 27** |
| EVRNA20 | QAV984104_1<br>QAV984104_2 | 1<br>2 | 8 to 12<br>4 to 6 | Q3<br>Q1, Q3 | Dry-ice | Qualitative | Viral EQA |
| **Enterovirus Typing (EV)** | | | | | | | **Pg 28** |
| EVTP20 | QAV164185_1 | 1 | 5 to 10 | Q1 | Dry-ice | Typing | Viral EQA |
| **Epstein-Barr virus (EBV)** | | | | | | | **Pg 28** |
| EBVDNA20 | QAV024121_1<br>QAV024121_2 | 1<br>2 | 8 to 12<br>4 to 6 | Q3<br>Q2, Q3 | Dry-ice | Qualitative & Quantitative | Viral EQA |
| **Epstein-Barr virus (EBV) Whole Blood** | | | | | | | **Pg 29** |
| EBVWB20 | QAV134161_1<br>QAV134161_2 | 1<br>2 | 8 to 12<br>4 to 6 | Q3<br>Q2, Q3 | Dry-ice | Qualitative & Quantitative | Viral EQA |
| **Extended Spectrum ß-lactamase and Carbapenemase** | | | | | | | **Pg 8** |
| ESBL20 | QAB134162_1 | 1 | 8 to 12 | Q3 | Dry-ice | Typing | Bacterial EQA |
| **Group B *Streptococcus*** | | | | | | | **Pg 9** |
| GBS20 | QAB174200_1 | 1 | 8 to 12 | Q4 | Dry-ice | Qualitative | Bacterial EQA |

| TARGET PATHOGEN | | | | | | | PAGE NUMBER |
|---|---|---|---|---|---|---|---|
| PROGRAMME CODE | CATALOGUE NUMBER | NO. OF CHALLENGES | PANEL MEMBERS PER CHALLENGE | DISTRIBUTION DATE(S)/ TESTING PERIOD | SHIPPING CONDITIONS | ANALYSIS TYPE | PROGRAMME TYPE |
| ***Helicobacter pylori*** | | | | | | | **Pg 9** |
| H.PYLORI20 | QAB164190_1 | 1 | 5 to 10 | Q3 | Dry-ice | Qualitative | Bacterial EQA |
| **Hepatitis A virus (HAV)** | | | | | | | **Pg 29** |
| HAVRNA20 | QAV124156_1<br>QAV124156_2 | 1<br>2 | 8 to 10<br>4 to 5 | Q3<br>Q1, Q3 | Dry-ice | Qualitative | Viral EQA |
| **Hepatitis B virus (HBV)** | | | | | | | **Pg 30** |
| HBVDNA20 | QAV994110_1<br>QAV994110_2<br>QAV994110_4 | 1<br>2<br>4 | 8<br>4<br>4 | Q3<br>Q1, Q3<br>Q1, Q2, Q3, Q4 | Dry-ice | Qualitative & Quantitative | Viral EQA |
| **Hepatitis B virus (HBV) Drug Resistance** | | | | | | | **Pg 30** |
| HBVDR20 | QAV124160_1 | 1 | 4 to 7 | Q3 | Dry-ice | Drug Resistance / Sequencing | Viral EQA |
| **Hepatitis B virus (HBV) Genotyping** | | | | | | | **Pg 31** |
| HBVGT20 | QAV064118_1 | 1 | 8 to 12 | Q1 | Dry-ice | Typing | Viral EQA |
| **Hepatitis C virus (HCV)** | | | | | | | **Pg 31** |
| HCVRNA20 | QAV994112_1<br>QAV994112_2<br>QAV994112_4 | 1<br>2<br>4 | 8<br>4<br>4 | Q3<br>Q1, Q3<br>Q1, Q2, Q3, Q4 | Dry-ice | Qualitative & Quantitative | Viral EQA |
| **Hepatitis C virus (HCV) Drug Resistance** | | | | | | | **Pg 32** |
| HCVDR20 | QAV134167_1 | 1 | 4 to 7 | Q3 | Dry-ice | Drug Resistance / Sequencing | Viral EQA |
| **Hepatitis C virus (HCV) Genotyping** | | | | | | | **Pg 32** |
| HCVGT20 | QAV034117_1 | 1 | 8 to 12 | Q1 | Dry-ice | Typing | Viral EQA |
| **Hepatitis D virus (HDV)** | | | | | | | **Pg 33** |
| HDV20 | QAV144170_1 | 1 | 8 to 10 | Q3 | Dry-ice | Qualitative & Quantitative | Viral EQA |
| **Hepatitis E virus (HEV)** | | | | | | | **Pg 33** |
| HEVRNA20 | QAV124157_1 | 1 | 8 to 10 | Q3 | Dry-ice | Qualitative | Viral EQA |
| **Herpes simplex virus 1 & 2 (HSV)** | | | | | | | **Pg 34** |
| HSVDNA20 | QAV994105_1<br>QAV994105_2 | 1<br>2 | 8 to 12<br>4 to 6 | Q3<br>Q1, Q3 | Dry-ice | Qualitative | Viral EQA |
| **Herpes simplex virus Drug Resistance** | | | | | | | **Pg 34** |
| HSVDR20 | QAV164184_1 | 1 | 4 to 7 | Q1 | Dry-ice | Sequence Analysis | Viral EQA |
| **Human Immunodeficiency virus type 2 (HIV-2)** | | | | | | | **Pg 47** |
| HIV2_20 | QAV204212_1<br>QAV204212_2 | 1<br>2 | 8<br>4 | Q1<br>Q1, Q3 | Dry-ice | Qualitative & Quantitative | Pilot Study |
| **Human herpes virus 6 (HHV6)** | | | | | | | **Pg 35** |
| HHV6DNA20 | QAV084119_1<br>QAV084119_2 | 1<br>2 | 8 to 12<br>4 to 6 | Q3<br>Q2, Q3 | Dry-ice | Qualitative & Quantitative | Viral EQA |
| **Human Immunodeficiency virus type 1 (HIV-1) – DNA** | | | | | | | **Pg 35** |
| HIVDNA20 | QAV034114_1<br>QAV034114_2 | 1<br>2 | 8<br>4 | Q3<br>Q1, Q3 | Dry-ice | Qualitative | Viral EQA |
| **Human Immunodeficiency virus type 1 (HIV-1) – Drug Resistance** | | | | | | | **Pg 36** |
| HIVDR20 | QAV024131_1 | 1 | 4 to 7 | Q3 | Dry-ice | Drug Resistance / Sequencing | Viral EQA |
| **Human Immunodeficiency virus type 1 (HIV-1) – Drug Resistance (Integrase)** | | | | | | | **Pg 36** |
| HIVDRint20 | QAV114146_1 | 1 | 4 to 7 | Q3 | Dry-ice | Drug Resistance / Sequencing | Viral EQA |

| TARGET PATHOGEN | | | | | | | PAGE NUMBER |
|---|---|---|---|---|---|---|---|
| PROGRAMME CODE | CATALOGUE NUMBER | NO. OF CHALLENGES | PANEL MEMBERS PER CHALLENGE | DISTRIBUTION DATE(S)/ TESTING PERIOD | SHIPPING CONDITIONS | ANALYSIS TYPE | PROGRAMME TYPE |
| **Human Immunodeficiency virus type 1 (HIV-1) – RNA** | | | | | | | **Pg 37** |
| HIVRNA20 | QAV994108_1<br>QAV994108_2<br>QAV994108_4 | 1<br>2<br>4 | 8<br>4<br>8 | Q3<br>Q1, Q3<br>Q1, Q2, Q3, Q4 | Dry-ice | Qualitative & Quantitative | Viral EQA |
| **Human metapneumovirus (MPV)** | | | | | | | **Pg 37** |
| MPV20 | QAV054135_1 | 1 | 8 to 12 | Q2 | Dry-ice | Qualitative | Viral EQA |
| **Human Papillomavirus (HPV) – PreservCyt** | | | | | | | **Pg 38** |
| HPVPRES20 | QAV094130_1<br>QAV094130_2 | 1<br>2 | 8 to 12<br>4 to 6 | Q4<br>Q2, Q4 | Ambient / Specialist | Qualitative | Viral EQA |
| **Human Papillomavirus (Surepath)** | | | | | | | **Pg 47** |
| HPVSURE20 | QAV184204_1 | 1 | 8 to 12 | Q4 | Ambient | Qualitative | Pilot Study |
| **Influenza A & B virus (FLU)** | | | | | | | **Pg 38** |
| INFRNA20 | QAV054134_1<br>QAV054134_2 | 1<br>2 | 8 to 12<br>4 to 6 | Q4<br>Q2, Q4 | Dry-ice | Qualitative | Viral EQA |
| **Influenza Haemagglutinin Typing** | | | | | | | **Pg 39** |
| INTP20 | QAV064138_1 | 1 | 5 to 10 | Q4 | Dry-ice | Typing | Viral EQA |
| **JC virus (JCV)** | | | | | | | **Pg 39** |
| JCDNA20 | QAV074106_1<br>QAV074106_2 | 1<br>2 | 8 to 12<br>4 to 6 | Q3<br>Q2, Q3 | Dry-ice | Qualitative & Quantitative | Viral EQA |
| ***Legionella pneumophila*** | | | | | | | **Pg 10** |
| LPDNA20 | QAB044122_1 | 1 | 8 to 12 | Q1 | Dry-ice | Qualitative | Bacterial EQA |
| **MALDI-TOF** | | | | | | | **Pg 17** |
| MALDI20 | QAB124155_1 | 1 | 8 to 12 | Q3 | Dry-ice | Typing | Multi-Pathogen / Syndromic EQA |
| **Measles / Mumps** | | | | | | | **Pg 40** |
| MM20 | QAV144171_1 | 1 | 8 to 12 | Q3 | Dry-ice | Qualitative | Viral EQA |
| **MERS coronavirus (MERS-CoV)** | | | | | | | **Pg 40** |
| MERS20 | QAV154181_1 | 1 | 6 to 10 | Q2 | Dry-ice | Qualitative | Viral EQA |
| **Methicillin Resistant *Staphylococcus aureus* (MRSA)** | | | | | | | **Pg 10** |
| MRSADNA20 | QAB064124_1 | 1 | 8 to 12 | Q2 | Ambient | Qualitative | Bacterial EQA |
| **Methicillin Resistant *Staphylococcus aureus* (MRSA) – Typing** | | | | | | | **Pg 11** |
| MRSATP20 | QAB074128_1 | 1 | 8 to 12 | Q2 | Ambient | Typing | Bacterial EQA |
| ***Mycobacterium tuberculosis* (MTB)** | | | | | | | **Pg 11** |
| MTBDNA20 | QAB014129_1<br>QAB014129_2 | 1<br>2 | 8 to 12<br>4 to 6 | Q4<br>Q2, Q4 | Ambient | Qualitative | Bacterial EQA |
| ***Mycobacterium tuberculosis* Drug Resistance** | | | | | | | **Pg 48** |
| MTBDR20 | QAB194209_1 | 1 | 6 to 10 | Q4 | Ambient | Typing | Pilot Study |
| ***Mycoplasma genitalium*** | | | | | | | **Pg 48** |
| MG20 | QAB184205_1 | 1 | 6 to 10 | Q3 | Dry-ice | Qualitative | Pilot Study |
| ***Mycoplasma pneumoniae*** | | | | | | | **Pg 12** |
| MP20 | QAB174192_1 | 1 | 5 to 10 | Q2 | Dry-ice | Qualitative | Bacterial EQA |

| TARGET PATHOGEN | | | | | | | PAGE NUMBER |
|---|---|---|---|---|---|---|---|
| PROGRAMME CODE | CATALOGUE NUMBER | NO. OF CHALLENGES | PANEL MEMBERS PER CHALLENGE | DISTRIBUTION DATE(S)/ TESTING PERIOD | SHIPPING CONDITIONS | ANALYSIS TYPE | PROGRAMME TYPE |
| ***Mycoplasma* spp. (cell contamination)** | | | | | | | **Pg 12** |
| MYCO20 | QAB144168_1 | 1 | 8 to 12 | Q4 | Dry-ice | Qualitative & Quantitative | Bacterial EQA |
| ***Neisseria gonorrhoeae*** | | | | | | | **Pg 13** |
| NgDNA20 | QAB034126_1<br>QAB034126_2 | 1<br>2 | 8 to 12<br>4 to 6 | Q3<br>Q1, Q3 | Dry-ice | Qualitative | Bacterial EQA |
| **Norovirus (NV)** | | | | | | | **Pg 41** |
| NVRNA20 | QAV084139_1<br>QAV084139_2 | 1<br>2 | 8 to 12<br>4 to 6 | Q4<br>Q2, Q4 | Dry-ice | Qualitative | Viral EQA |
| **Parainfluenza virus (PIV)** | | | | | | | **Pg 41** |
| PINFRNA20 | QAV064136_1 | 1 | 8 to 12 | Q2 | Dry-ice | Qualitative | Viral EQA |
| **Parasitic Gastroenteritis** | | | | | | | **Pg 18** |
| GastroP20 | QAP124154_1<br>QAP124154_2 | 1<br>2 | 8 to 12<br>4 to 6 | Q4<br>Q2 & Q4 | Dry-ice | Qualitative | Multi-Pathogen / Syndromic EQA |
| **Parechovirus (HPeV)** | | | | | | | **Pg 42** |
| PeVRNA20 | QAV114145_1<br>QAV114145_2 | 1<br>2 | 8 to 12<br>4 to 6 | Q3<br>Q1, Q3 | Dry-ice | Qualitative | Viral EQA |
| ***Pneumocystis jirovecii pneumonia* (PCP)** | | | | | | | **Pg 16** |
| PCPDNA20 | QAF114144_1 | 1 | 8 to 12 | Q3 | Dry-ice | Qualitative & Quantitative | Fungal EQA |
| **Respiratory I** | | | | | | | **Pg 18** |
| RESPI20 | QAV164188_1<br>QAV164188_2 | 1<br>2 | 8 to 12<br>4 to 6 | Q3<br>Q1, Q3 | Dry-ice | Qualitative | Multi-Pathogen / Syndromic EQA |
| **Respiratory II** | | | | | | | **Pg 19** |
| RESPII20 | QAV164189_1<br>QAV164189_2 | 1<br>2 | 8 to 12<br>4 to 6 | Q3<br>Q1, Q3 | Dry-ice | Qualitative | Multi-Pathogen / Syndromic EQA |
| **Respiratory III** | | | | | | | **Pg 19** |
| RESPIII20 | QAM174193_1<br>QAM174193_2 | 1<br>2 | 8 to 12<br>4 to 6 | Q3<br>Q1, Q3 | Dry-ice | Qualitative | Multi-Pathogen / Syndromic EQA |
| **Respiratory syncytial virus (RSV)** | | | | | | | **Pg 42** |
| RSV20 | QAV054142_1<br>QAV054142_2 | 1<br>2 | 8 to 12<br>4 to 6 | Q4<br>Q2, Q4 | Dry-ice | Qualitative | Viral EQA |
| **Rhinovirus (RV)** | | | | | | | **Pg 43** |
| RVRNA20 | QAV064143_1 | 1 | 8 to 12 | Q2 | Dry-ice | Qualitative | Viral EQA |
| **Sepsis** | | | | | | | **Pg 49** |
| SEPSIS20 | QAB164178_1 | 1 | 8 to 12 | Q4 | Dry-ice | Qualitative | Multi-Pathogen / Syndromic EQA |
| **Sexually Transmitted Infections I** | | | | | | | **Pg 20** |
| STI_I20 | QAB154177_1<br>QAB154177_2 | 1<br>2 | 8 to 12<br>4 to 6 | Q3<br>Q2, Q3 | Dry-ice | Qualitative | Multi-Pathogen / Syndromic EQA |
| **Sexually Transmitted Infections II** | | | | | | | **Pg 20** |
| STI_II20 | QAM174201_1<br>QAM174201_2 | 1<br>2 | 8 to 12<br>4 to 6 | Q3<br>Q2, Q3 | Dry-ice | Qualitative | Multi-Pathogen / Syndromic EQA |

| TARGET PATHOGEN | | | | | | | PAGE NUMBER |
|---|---|---|---|---|---|---|---|
| PROGRAMME CODE | CATALOGUE NUMBER | NO. OF CHALLENGES | PANEL MEMBERS PER CHALLENGE | DISTRIBUTION DATE(S)/ TESTING PERIOD | SHIPPING CONDITIONS | ANALYSIS TYPE | PROGRAMME TYPE |
| ***Staphylococcus aureus spa*** | | | | | | | **Pg 13** |
| SASPA20 | QAB134164_1 | 1 | 6 to 12 | Q2 | Ambient | Typing | Bacterial EQA |
| **Syphilis** | | | | | | | **Pg 14** |
| SYPH20 | QAB154180_1 | 1 | 5 to 10 | Q4 | Dry-ice | Qualitative | Bacterial EQA |
| **Torque teno virus (TTV)** | | | | | | | **Pg 49** |
| TTV20 | QAV184203_1 | 1 | 6 to 10 | Q4 | Dry-ice | Qualitative | Pilot Study |
| ***Toxoplasma gondii*** | | | | | | | **Pg 22** |
| TGDNA20 | QAP044123_1<br>QAP044123_2 | 1<br>2 | 8 to 12<br>4 to 6 | Q4<br>Q2, Q4 | Ambient | Qualitative | Parasitic EQA |
| **Transplantation (viral)** | | | | | | | **Pg 50** |
| TRANS20 | QAM174198_1<br>QAM174198_2 | 1<br>2 | 8 to 12<br>4 to 6 | Q3<br>Q2, Q4 | Dry-ice | Qualitative & Quantitative | Pilot Study |
| ***Trichomonas vaginalis*** | | | | | | | **Pg 50** |
| TV20 | QAP184202_1 | 1 | 6 to 10 | Q3 | Dry-ice | Qualitative | Pilot Study |
| **Vancomycin Resistant Enterococci (VRE)** | | | | | | | **Pg 14** |
| VRE20 | QAB134163_1 | 1 | 8 to 12 | Q3 | Dry-ice | Qualitative | Bacterial EQA |
| **Varicella-Zoster virus (VZV)** | | | | | | | **Pg 43** |
| VZVDNA20 | QAV034103_1<br>QAV034103_2 | 1<br>2 | 8 to 12<br>4 to 6 | Q3<br>Q1, Q3 | Dry-ice | Qualitative | Viral EQA |
| **Viral Gastroenteritis** | | | | | | | **Pg 21** |
| GastroV20 | QAV124152_1<br>QAV124152_2 | 1<br>2 | 8 to 12<br>4 to 6 | Q4<br>Q2, Q4 | Dry-ice | Qualitative | Multi-Pathogen / Syndromic EQA |
| **Viral Metagenomics NGS** | | | | | | | **Pg 51** |
| NGSmta_20 | QAV204213_1 | 1 | 4 to 7 | Q4 | Dry-ice | Qualitative | Viral EQA |
| **West Nile virus (WNV)** | | | | | | | **Pg 44** |
| WNVRNA20 | QAV104141_1 | 1 | 8 to 12 | Q2 | Ambient | Qualitative | Viral EQA |
| **Yellow fever virus** | | | | | | | **Pg 51** |
| YFV20 | QAM194207_1 | 1 | 8 to 12 | Q2 | Ambient | Qualitative | Pilot Study |
| **Zika virus** | | | | | | | **Pg 44** |
| ZIKA20 | QAV164186_1 | 1 | 8 to 12 | Q2 | Ambient | Qualitative | Viral EQA |



www.qcmd.org

UKAS PROFICIENCY TESTING
4385

LT739 SEP19

RANDOX

Randox is a non-exclusive distribution partner of QCMD within selected countries.
Contact your regional representative or **marketing@randox.com** for more details.